[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 52 of about 52
1. Suzuki K, Hoshi S, Orikasa S: Recurrence pattern of metastatic testicular cancers after chemotherapy. Tohoku J Exp Med; 2001 May;194(1):17-22
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence pattern of metastatic testicular cancers after chemotherapy.
  • Recurrence pattern of metastatic testicular cancer after the initial treatment was investigated.
  • Seventy-seven patients with metastatic testicular cancer were treated by cisplatin-based chemotherapy.
  • Patients with residual masses after chemotherapy and whose tumor markers were normalized underwent surgical resections.
  • Of the 77 patients, 61 achieved cancer free status and 4 who did not need the study criteria excluded.
  • Recurrences were detected in 12 (21.1%) patients, 2 (7.1%) patients among 28 stage II patients; 10 (34.5%) patients among 29 stage III patients; none (0%) patients among 14 seminoma patients and 12 (27.9%) patients among 43 non-seminoma patients.
  • All recurrences were detected within 17 months (median, 3) after the initial treatment.
  • Of the 12 patients experiencing recurrence, 4 died of cancer.
  • The recurrence rate of the patients in stage III was significantly higher than that in stage II.
  • Follow-up studies after treatment should include serum tumor markers and computed tomographic scanning of lung, abdomen and pelvis at defined intervals.
  • Intensive follow-up will be needed especially for the patients in stage III and with non-seminoma.
  • Follow-up within the first two years is especially important in detecting recurrence after chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Seminoma / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Follow-Up Studies. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Neoplasm Metastasis. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11556730.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


2. Brandli DW, Ulbright TM, Foster RS, Cummings OW, Zhang S, Sweeney CJ, Eble JN, Cheng L: Stroma adjacent to metastatic mature teratoma after chemotherapy for testicular germ cell tumors is derived from the same progenitor cells as the teratoma. Cancer Res; 2003 Sep 15;63(18):6063-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stroma adjacent to metastatic mature teratoma after chemotherapy for testicular germ cell tumors is derived from the same progenitor cells as the teratoma.
  • Metastatic mature teratoma is often present in postchemotherapy surgical specimens of lymph nodes from patients with pathological stage II or III testicular germ cell tumors.
  • The stromal cells in these lesions have generally been considered "fibrosis" secondary to the chemotherapy and the necrosis it causes, although the frequent cytological atypia of the stromal cells suggests that they may be neoplastic.
  • We studied 25 patients with pathological stage II or III testicular cancer who were treated with platinum-based chemotherapy followed by surgical resection of retroperitoneal lymph nodes that contained metastatic mature teratoma with "fibrosis" to determine the reactive or neoplastic nature of the stromal cells.
  • A laser capture microdissection technique facilitated preparation of genomic DNA from the epithelial components of teratoma, adjacent stromal cells, and normal lymph node tissue from each patient.
  • Concordant genetic alterations observed in teratoma and stroma suggest that both are derived from the same element of the original germ cell tumor or the same progenitor cell.
  • [MeSH-major] Neoplastic Stem Cells / pathology. Teratoma / genetics. Teratoma / pathology. Testicular Neoplasms / genetics. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Embryonal Carcinoma Stem Cells. Humans. Loss of Heterozygosity. Male. Neoplasm Metastasis. Stromal Cells / pathology

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14522936.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Ehrlich Y, Yossepowitch O, Kedar D, Baniel J: Distribution of nodal metastases after chemotherapy in nonseminomatous testis cancer: a possible indication for limited dissection. BJU Int; 2006 Jun;97(6):1221-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of nodal metastases after chemotherapy in nonseminomatous testis cancer: a possible indication for limited dissection.
  • OBJECTIVE: To assess the clinical and pathological findings of patients treated by bilateral retroperitoneal lymph node dissection (RPLND) after chemotherapy, to identify a subset for whom modified template nodal resection might be contemplated, as bilateral RPLND is the treatment of choice in patients with residual retroperitoneal disease after chemotherapy for nonseminomatous germ-cell tumour (GCT).
  • PATIENTS AND METHODS: The medical records were reviewed of 50 consecutive patients who had RPLND after chemotherapy between 1996 and 2005.
  • The pathological findings were correlated with the side of the primary lesion and the extent of metastatic disease before chemotherapy.
  • RESULTS: Pathological assessment of the resected lymph nodes revealed teratoma in 28 patients (56%), viable carcinoma in three (6%), and necrosis or fibrosis in 19 (38%).
  • All clinical stage Is, IIA and IIB left-sided primary tumours followed a predictable pattern of spread constricted to a modified left-sided template.
  • Patients with clinical stage IIC and III, or right-sided primary tumour, had a less predictable metastatic pattern, having crossover metastases to the contralateral template.
  • CONCLUSION: Bilateral RPLND should be considered as the reference standard in patients with metastatic GCT and residual retroperitoneal mass after completing chemotherapy.
  • However, the present data suggest that a modified template dissection might be considered even after chemotherapy in patients with left-sided primary tumours and limited nodal involvement at presentation.
  • [MeSH-major] Lymph Node Excision / methods. Neoplasm, Residual / surgery. Neoplasms, Germ Cell and Embryonal / surgery. Testicular Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Retroperitoneal Space. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16686715.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Mezvrishvili ZN: [Modified chemotherapy regimens in selected testicular cancer patients with good prognosis]. Georgian Med News; 2006 Jun;(135):7-12
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Modified chemotherapy regimens in selected testicular cancer patients with good prognosis].
  • The goal of our study was to assess the feasibility of usage of chemotherapy regimens with reduced intensity in subgroups of selected patients with good-prognosis metastatic nonseminomatous germ cell tumor (NSGCT) of the testis.
  • 18 patients with low-volume stage II NSGCT who achieved normal tumor marker level after the first cycle of cisplatin, etoposide and bleomycin (BEP) chemotherapy (group 1) received etoposide and cisplatin (EP) as second and third cycles of treatment and 15 testicular cancer patients with serological disease only (group 2) underwent three cycles of EP chemotherapy.
  • The chemotherapy-related side effects observed in these patients were compared with those in control group consisting of 93 good-prognosis metastatic patients treated with three standard cycles of BEP.
  • All patients from both groups achieved complete response with chemotherapy alone (14 group 1 and 15 group 2 patients) or by subsequent resection of teratoma or necrosis (4 cases from group 1).
  • No relapse with viable malignancy was observed after the treatment.
  • Compared to the control group, less number of treatment cycles was associated with grade III-IV leucopenia in groups 1 (p=0.07) and 2 (p=0.03).
  • Reduced intensity chemotherapy regimens showed efficacy equal to the standard treatment and can be considered as less toxic therapeutic options in these selected patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Humans. Male. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16905797.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Georgia (Republic)
  •  go-up   go-down


5. Oechsle K, Hartmann M, Brenner W, Venz S, Weissbach L, Franzius C, Kliesch S, Mueller S, Krege S, Heicappell R, Bares R, Bokemeyer C, de Wit M, German Multicenter Positron Emission Tomography Study Group: [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol; 2008 Dec 20;26(36):5930-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group.
  • PURPOSE: In patients with metastatic nonseminomatous germ cell cancer (NSGCT), residual masses after chemotherapy (CTX) can consist of vital carcinoma, mature teratoma, or necrosis.
  • This prospective trial has evaluated the accuracy of [(18)F]fluorodeoxyglucose positron emission tomography (FDG-PET) for the prediction of histology compared with computed tomography (CT) and serum tumor markers (STM).
  • PATIENTS AND METHODS: A total of 121 patients with stage IIC or III NSGCT scheduled for secondary resection after cisplatin-based CTX were included.
  • RESULTS: Prediction of tumor viability with FDG-PET was correct in 56%, which did not reach the expected clinically relevant level of 70%, and was not better than the accuracy of CT (55%) or STM (56%).
  • Judging only vital carcinoma as a true malignant finding, the negative predictive value increased to 83% for FDG-PET.
  • CONCLUSION: The presence of vital carcinoma and mature teratoma is common (55%) in residual masses in patients with NSGCT, and CT and STM cannot reliably predict absence of disease.
  • In contrast to prior studies, this prospective trial, which is the only with histologic confirmation in all patients, demonstrated that FDG-PET is unable to give a clear additional clinical benefit to the standard diagnostic procedures, CT and STM, in the prediction of tumor viability in residual masses.
  • [MeSH-major] Neoplasm, Residual / radionuclide imaging. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / radionuclide imaging. Positron-Emission Tomography. Testicular Neoplasms / drug therapy. Testicular Neoplasms / radionuclide imaging
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / blood. Cell Survival. Cisplatin / therapeutic use. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / radionuclide imaging. Retroperitoneal Neoplasms / surgery. Sensitivity and Specificity. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19018083.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0Z5B2CJX4D / Fluorodeoxyglucose F18; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Ondrus D, Hornák M, Breza J, Mat'oska J, Schnorrer M, Belan V, Kausitz J: Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer. Int Urol Nephrol; 2001;32(4):665-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer.
  • INTRODUCTION: The therapeutic procedures in the management of testicular cancer are determined by histological findings in the removed testis and by the extent of the disease at the time of diagnosis.
  • However, all advanced tumors could be treated by primary chemotherapy regardless of the histological findings.
  • The current imaging techniques (ultrasound of the testis, abdominal and chest CT examination) and laboratory tests (determination of serum tumor markers AFP and hCG) provide sufficient evidence for the presence of cancer.
  • When the diagnosis of advanced tumor is evident, it is possible to start the treatment without orchiectomy.
  • The aim of this study was to evaluate the advantages of neo-adjuvant chemotherapy with delayed orchiectomy in the management of advanced testicular cancer.
  • MATERIAL AND METHODS: A total of 36 patients with advanced germ cell testicular cancer underwent primary PVB or BEP chemotherapy without previous orchiectomy.
  • Searching for the origin, testicular tumor was detected.
  • Eleven patients had a bulky disease in the retroperitoneum (Stage IIC), two had enlarged retroperitoneal lymph nodes (Stage IIB), two had enlarged mediastinal lymph nodes (Stage III) and other 16 patients had also pulmonary metastases, and 5 pts had pulmonary metastases only.
  • The patients were treated with cisplatin-containing combination chemotherapy.
  • Following completion of chemotherapy, orchiectomy was performed alone or simultaneously with retroperitoneal lymph node dissection (RPLND) and/or lung metastasectomy in cases with persistent residual mass.
  • Following orchiectomy the patients were regularly checked and in cases with viable malignant tumor found in the testis sequential chemotherapy was administered.
  • Similarly when the relapse of the disease was detected, the patients were treated with sequential chemotherapy.
  • RESULTS: Complete disappearance of metastases was observed in 12 patients following chemotherapy alone.
  • The viable tumor in the removed tissue was found in one patient.
  • Delayed orchiectomy was performed simultaneously with surgical removal of residual mass in the retroperitoneum in 24 patients and as a separate procedure in 12 patients who have been considered to be complete responders following chemotherapy alone.
  • Residual viable tumor in testicular specimen was found in three patients, necrotic or fibrotic tissue in 18, and mature teratoma in 15 patients.
  • Overall survival of the patients was 26/36 (72.7%) at mean of 56.9 months (range 7-145 months, median 50 months) since the start of the treatment.
  • CONCLUSIONS: In patients with advanced germ cell testicular cancer preference must be given to the early beginning of intensive chemotherapy without the need of tissue diagnosis of primary tumor that should be obtained by orchiectomy.
  • Benefit of this therapeutic approach is the timely management of acute abdominal and/or pulmonary symptoms of life-threatening distant metastases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Cisplatin / therapeutic use. Germinoma / drug therapy. Orchiectomy. Testicular Neoplasms / drug therapy. Vinblastine / therapeutic use
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm, Residual. Survival Rate. Teratoma / secondary. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1984 Sep;2(9):1025-7 [6088708.001]
  • [Cites] J Urol. 1983 Mar;129(3):522-3 [6834536.001]
  • [Cites] J Urol. 1996 Mar;155(3):952-4 [8583615.001]
  • [Cites] Br J Cancer. 1983 May;47(5):613-9 [6189504.001]
  • [Cites] Cancer. 1995 Feb 15;75(4):1018-24 [7842403.001]
  • [Cites] Ann Intern Med. 1977 Sep;87(3):293-8 [71004.001]
  • [Cites] J Urol. 1986 Dec;136(6):1221-3 [3022018.001]
  • (PMID = 11989561.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; PVB protocol
  •  go-up   go-down


7. Beck SD: Optimal management of testicular cancer: from self-examination to treatment of advanced disease. Open Access J Urol; 2010;2:143-54

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimal management of testicular cancer: from self-examination to treatment of advanced disease.
  • Germ-cell cancer is the most common solid tumor in men aged 15 to 35 years and has become the model for curable neoplasm.
  • This improved cure rate has been largely attributed to the introduction of cisplatin-based chemotherapy.
  • In stage I seminoma and nonseminoma, cure rates approach 100% and treatment is governed by patient choice based on the perceived morbidities of each therapy and personal preferences.
  • For seminoma, treatments include surveillance, radiotherapy, and single course carboplatin.
  • For nonseminoma, treatments include surveillance, retroperitoneal lymph node dissection (RPLND), and adjuvant chemotherapy.
  • Low volume (<3 cm) stage II seminoma is typically managed with radiotherapy while higher volume (>3 cm) stage II and stage III disease treated with chemotherapy.
  • Positron emission tomography (PET) imaging can differentiate active cancer versus necrosis for postchemotherapy residual masses.
  • PET-positive masses are managed with either surgery or second-line chemotherapy.
  • Low volume (<5 cm) stage II nonseminoma with normal serum tumor markers may be managed with either RPLND or chemotherapy.
  • Patients with persistently elevated serum tumor markers and larger volume stage II and stage III disease are managed with systemic chemotherapy.
  • Residual postchemotherapy masses should be resected due to the uncertainty of the histology with 50% to 60% harboring residual teratoma or active cancer.
  • The majority of patients completing initial therapy who relapse do so within 2 years.
  • Current therapeutic challenges in testis cancer include the accurate prediction of postchemotherapy histology to avoid surgery in patients harboring fibrosis only, improved therapy in platinum-resistant and platinum-refractory disease, and the understanding of the biology of late relapse.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24198622.001).
  • [ISSN] 1179-1551
  • [Journal-full-title] Open access journal of urology
  • [ISO-abbreviation] Open Access J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3818885
  • [Keywords] NOTNLM ; advanced disease / self-examination / testicular cancer
  •  go-up   go-down


8. Abd El-Aal HH, Habib EE, Mishrif MM: Rhabdomyosarcoma: the experience of the pediatric unit of Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine (NEMROCK) (from January 1992 to January 2001). J Egypt Natl Canc Inst; 2006 Mar;18(1):51-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our present study is a retrospective analysis of the treatment results of new rhabdomyosarcoma pediatric patients who had attended the pediatric unit clinic of Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine (NEMROCK) from January 1992 to January 2001).
  • Stage I, II orbital and stage I para-testicular embryonal rhabdomyosarcomas received 32 weeks of vincristine and actinomycin- D (vincristine 1.5 mg/m2 weekly, actinomycin-D 0.015 mg/Kg/day day 1 to day 5).
  • Other pathologies, sites and stages received 52 weeks of chemotherapy.
  • Chemotherapy regimens included VAC (vincristine 1.5 mg/m2 weekly, actinomycin-D 0.015 mg/Kg/day day 1 to day 5 and endoxan 2.2 gm/m2 I.V with mesna every 21 days), VAI (vincristine, actinomycin-D and ifosfamide 1.8 gm/m2 I.V day 1 to day 5 with mesna) or VIE (vincristine, ifosfamide and vepesid 100 mg/m2 I.V day 1 to day 5) [11,12].
  • Stages I and II received conventional fractionation radiotherapy 4140 cGy on week 13, stages III and IV received conventional fractionation radiation therapy 5040 cGy also, on week 13.
  • The radiation volume included the tumor bed with a 2 cm safety margin at least.
  • Relapsing cases received palliative radiation therapy and chemotherapy (cisplatinum I.V 100 mg/m2 divided over 2 days and vepesid 100 mg/m2 I.V day 1 to day 3 to be recycled every 21 days).
  • Overall survival, disease free survival, treatment response, and complications of treatment were assessed and statistically analyzed.
  • Pathologically, embryonal type was the commonest statistically (48/55, i.e.
  • 87.3%) compared to the alveolar type (7/55, i.e. 12.7%).
  • Concerning site of the primary tumor it was found to be highest in the head and neck (20/55, i.e.
  • CONCLUSION: Despite the advances in the therapy of rhabdomyosarcoma.
  • The factors determining the 5-year survival after relapse at the time of initial diagnosis include histological subtype, and disease cluster.
  • [MeSH-major] Rhabdomyosarcoma / mortality. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Neoplasm Staging. Prognosis. Radiotherapy. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237856.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


9. Albers P, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann KU, Fimmers R, Weissbach L, Loy V, Wittekind C, Hartmann M, German Testicular Cancer Study Group: Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol; 2008 Jun 20;26(18):2966-72
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
  • PURPOSE: Retroperitoneal lymph node dissection (RPLND) and adjuvant chemotherapy are two adjuvant treatment options for patients with clinical stage I nonseminomatous germ cell tumors of the testis (NSGCT).
  • Aim of this trial was to prove the advantage of one cycle of bleomycin, etoposide, and cisplatin (BEP) chemotherapy compared with RPLND in terms of recurrence.
  • The trial was powered to detect a 7% reduction (from 10% to 3%) of recurrence with chemotherapy compared with surgery.
  • RESULTS: After a median follow-up of 4.7 years, two and 15 recurrences were observed in the intention-to-treat population with chemotherapy and surgery, respectively (P = .0011).
  • The difference in the 2-year recurrence-free survival rate between chemotherapy (99.46%; 95% CI, 96.20% to 99.92%) and surgery (91.87%; 95% CI, 86.87% to 95.02%) was 7.59% (95% CI, 3.13% to 12.05%).
  • The hazard ratio to experience a tumor recurrence with surgery as opposed to chemotherapy was 7.937 (95% CI, 1.808 to 34.48).
  • CONCLUSION: To our knowledge, this is the largest randomized trial investigating adjuvant treatment strategies in clinical stage I NSGCT, which showed the superiority of one course BEP over RPLND performed according to community standards to prevent recurrence.
  • Although not standard treatment, one course of BEP is active in an unselected group of patients with clinical stage I disease and merits further investigation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / surgery. Testicular Neoplasms / drug therapy. Testicular Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Disease-Free Survival. Etoposide / administration & dosage. Etoposide / adverse effects. Humans. Lymph Node Excision / adverse effects. Lymph Node Excision / methods. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Orchiectomy

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Jun 20;26(18):2934-6 [18458042.001]
  • [CommentIn] J Clin Oncol. 2009 May 1;27(13):2114-6 [19307494.001]
  • [ErratumIn] J Clin Oncol. 2010 Mar 10;28(8):1439. Dosage error in article text
  • (PMID = 18458040.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Tandstad T, Cohn-Cedermark G, Dahl O, Stierner U, Cavallin-Stahl E, Bremnes RM, Klepp O: Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study. Ann Oncol; 2010 Sep;21(9):1858-63
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study.
  • BACKGROUND: To offer minimized risk-adapted adjuvant treatment on a community and nationwide basis for patients with clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT).
  • The aim was to reduce the risk of relapse and thereby reducing the need of later salvage chemotherapy while maintaining a high cure rate.
  • All were eligible for inclusion into one of two community-based multicenter Swedish and Norwegian Testicular Cancer Project (SWENOTECA) III studies.
  • One study was a prospective randomized study for patients without vascular invasion in the testicular tumor (VASC-), evaluating the effect of one adjuvant course of cisplatin, vinblastine and bleomycin (CVB) compared with surveillance.
  • As all remaining patients were managed according to the SWENOTECA III protocol, although not randomized, the data were pooled.
  • Adjuvant CVB chemotherapy has no place in the treatment of CS1 NSGCT.

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20142410.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Cushing B, Giller R, Cullen JW, Marina NM, Lauer SJ, Olson TA, Rogers PC, Colombani P, Rescorla F, Billmire DF, Vinocur CD, Hawkins EP, Davis MM, Perlman EJ, London WB, Castleberry RP, Pediatric Oncology Group 9049, Children's Cancer Group 8882: Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882. J Clin Oncol; 2004 Jul 1;22(13):2691-700
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.
  • PURPOSE: To determine in a randomized comparison whether combination chemotherapy with high-dose cisplatin (HDPEB) improves the event-free (EFS) and overall (OS) survival of children and adolescents with high-risk malignant germ cell tumors (MGCT) as compared with standard-dose cisplatin (PEB) and to compare the regimens' toxicity.
  • PATIENTS AND METHODS: Between March 1990 and February 1996, 299 eligible patients with stage III and IV gonadal and extragonadal (all stages) MGCT were enrolled onto this Pediatric Oncology Group and Children's Cancer Group study.
  • Chemotherapy included bleomycin 15 units/m(2) on day 1, etoposide 100 mg/m(2) on days 1 through 5, and either high-dose cisplatin 40 mg/m(2) on days 1 through 5 (HDPEB; n = 149) or standard-dose cisplatin 20 mg/m(2) on days 1 through 5 (PEB; n = 150).
  • Patients were evaluated after four cycles of therapy, and those with residual disease underwent surgery.
  • RESULTS: One hundred thirty-four eligible patients with advanced testicular (n = 60) or ovarian (n = 74) tumors and 165 with stage I to IV extragonadal tumors were enrolled.
  • HDPEB treatment resulted in significantly improved 6-year EFS rate +/- SE (89.6% +/- 3.6% v 80.5% +/- 4.8% for PEB; P =.0284).
  • Tumor-related deaths were more common after PEB (14 deaths v two deaths).
  • Other treatment-related toxicities were more common with HDPEB.
  • CONCLUSION: Combination chemotherapy with HDPEB significantly improves EFS for children with high-risk MGCT.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Neoplasms, Germ Cell and Embryonal / drug therapy. Ovarian Neoplasms / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Bleomycin. Child. Child, Preschool. Disease-Free Survival. Dose-Response Relationship, Drug. Etoposide. Female. Humans. Male. Prognosis. Risk Factors

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15226336.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA13539; United States / NCI NIH HHS / CA / CA30969; United States / NCI NIH HHS / CA / U10CA29139
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


12. Scholz M, Höltl W: Stage I testicular cancer. Curr Opin Urol; 2003 Nov;13(6):473-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage I testicular cancer.
  • PURPOSE OF REVIEW: To review current developments in the management of patients with testicular cancer, with special emphasis on risk factors for the primary tumour and treatment options for clinical stage I testicular germ cell tumours.
  • RECENT FINDINGS: The management of patients with testicular cancer has substantially improved over the past 25 years.
  • Current concepts for treating localized and regional disease have been influenced by effective systematic chemotherapy.
  • At present, cure rates approach nearly 100% for low-stage disease and more than 80% for advanced disease.
  • SUMMARY: Retroperitoneal lymph node dissection is still favoured as the therapy of choice for clinical stage I non-seminomatous germ cell tumours in many centres, but as risk factors for the primary tumour have become better understood, surveillance and risk-adapted therapy, including surveillance for low-risk patients and adjuvant chemotherapy for the high-risk group, is now being considered a therapeutic option particularly in European centres.
  • Adjuvant radiotherapy is still the gold standard for the treatment of patients with clinical stage I seminoma, but the relapse rate of 19% and a 5-year overall survival of 97.7% make surveillance a possible therapeutic option.
  • The results of phase II and III trials should soon provide additional information on carboplatin for single-agent adjuvant chemotherapy.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / surgery. Testicular Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Male. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14560141.001).
  • [ISSN] 0963-0643
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


13. Garcia Del Muro X, Maroto P, Gumá J, López Brea M, Sastre J, Arranz JA, Lainez N, López Lara F, Berenguer G, Germá-Lluch JR: Chemotherapy as an alternative to radiotherapy in the treatment of stages IIA/B testicular seminoma: A Spanish Germ Cell Cancer Group study. J Clin Oncol; 2004 Jul 15;22(14_suppl):4530

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy as an alternative to radiotherapy in the treatment of stages IIA/B testicular seminoma: A Spanish Germ Cell Cancer Group study.
  • : 4530 Background: Radiotherapy (RT) is considered the standard treatment for stages IIA/B testicular seminoma.
  • As chemotherapy (CT) is highly effective in advanced disease and in recurrences after RT, we have developed a multicenter prospective protocol of treatment with CT in patients (pts) with stages IIA/B seminoma.
  • METHODS: We studied 71 consecutive pts with stages IIA and IIB testicular seminoma, initially treated with cisplatin-based chemotherapy, from April 1994 to March 2003 in 26 centers.
  • Patient characteristics were: median age 38 (27-84) years; 18 pts had stage IIA and 53 had stage IIB; 11 of these pts had had a relapse of a previous stage I on surveillance; 8 pts had high BHCG levels.
  • The treatment administered was: EP (etoposide, cisplatin) in 62 and BEP (bleomycin, etoposide, cisplatin) in 9 pts.
  • Hematological toxicity was: Granulocytopenia G-IV:1 pts, G-III: 3, G-II: 6; Thrombocytopenia G-III:2, G-II:2; Anemia G-III:1, G-II:1; Extrahematological toxicity was: Nausea/Vomiting G-III:6, G-II:16, Stomatitis GIII: 1, G-II: 3, Diarrhea G-III:1; Pulmonary toxicity G-III:1; Neurotoxicity G-II:4; Skin rash G-II:1.
  • Our results support the role of CT as an alternative to RT in the treatment of these pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016062.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Fernández Gómez JM, Escaf Barmadah S, Guate Ortiz JL, Martín Huescar A, Fresno Forcelledo F, García Rodríguez J, Rodríguez Faba O, Jalón Monzón A, Rodríguez Martínez JJ: [Urologic treatment of testicular germ cell cancer]. Arch Esp Urol; 2002 Oct;55(8):927-36
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urologic treatment of testicular germ cell cancer].
  • [Transliterated title] Tratamiento urológico del cáncer germinal de testículo.
  • OBJECTIVE: To review the treatment of testicular germ-cell cancer in our series.
  • METHODS: 73 cases with the diagnosis of germ-cell testicular tumours were reviewed.
  • We reviewed the treatment options employed in our series, analysing different currently recognised risk factors.
  • RESULTS: 34 out of 73 testicular germ-cell tumours were seminomas (46.6%) and 39 non seminomas (54.4%).
  • Clinically 58.9% of the patients had localised, stage I tumours.
  • 85.7% seminomas were stage I at presentation compared to 35.9% (14) non seminomatous tumours.
  • The remainder tumours presented in advanced phases (stages II & III).
  • Inguinal orchiectomy was performed in all cases except 5 patients in whom tumours were incidentally diagnosed (atrophic testis orchiectomy, hydrocelectomy, trauma) and underwent ipsilateral scrotal excision in a second time.
  • 30 patients received chemotherapy after orchiectomy: 3 metastatic seminomas (stage II) (8.8% of seminomas treated with chemotherapy) and 27 non seminomatous tumours (69.2% of them).
  • All metastatic tumours are among the last (25) (Stages II & III) and 2 stage I non seminomatous tumours.
  • Median time to relapse was 4 months (2-102).
  • CONCLUSIONS: Testicular germ-cell cancer needs a well established multidisciplinary approach, in which the role of the urologist is fundamental.
  • Orchiectomy is the primary treatment and allows determination of the dissemination risk.
  • Radiotherapy is very effective for localised seminomas with poor prognostic factors, and for non seminomas 2 cycles of chemotherapy seem to be an effective approach, as well as of little toxicity.
  • We must know and apply optimised programs for observation of these tumours (stage I), and also use follow-up protocols after chemotherapy or radiotherapy.
  • Some cases need complex surgery for residual masses resection or post chemotherapy salvage surgery in disseminated tumours (Stages II & III).
  • Sterility treatment protocols are applied to preserve fertility.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / surgery. Orchiectomy. Testicular Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retroperitoneal Neoplasms / secondary. Seminoma / drug therapy. Seminoma / pathology. Seminoma / radiotherapy. Seminoma / surgery. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12455283.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 25
  •  go-up   go-down


15. Hartmann M, Siener R, Krege S, Schmelz H, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann KU, Fimmers R, Weissbach L, Loy V, Wittekind C, Albers P, German Testicular Cancer Study Group: [Results of the randomised phase III study of the German Testicular Cancer Study Group. Retroperitoneal lymphadenectomy versus one cycle BEP as adjuvant therapy for non-seminomatous testicular tumours in clinical stage I]. Urologe A; 2009 May;48(5):523-8
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of the randomised phase III study of the German Testicular Cancer Study Group. Retroperitoneal lymphadenectomy versus one cycle BEP as adjuvant therapy for non-seminomatous testicular tumours in clinical stage I].
  • [Transliterated title] Ergebnisse der randomisierten Phase-III-Studie der "German Testicular Cancer Study Group". Retroperitoneale Lymphadenektomie vs. 1 Zyklus PEB als adjuvante Therapie beim nichtseminomatösen Hodentumor im klinischen Stadium I.
  • OBJECTIVE: As 30% of non-seminomas in clinical stage I will progress during active surveillance, alternative adjuvant strategies of 2 cycles of bleomycin, etoposid, cisplatin (BEP) or nerve sparing retroperitoneal lymphadenectomy (RPLND) can be offered.
  • RESULTS: After a mean follow-up of 4.7 years, there were 2 and 13 recurrences in the according-to-protocol population with chemotherapy and surgery, respectively.
  • The difference between chemotherapy (1.15%) and surgery (7.5%) was statistically significant (p=0.0033).
  • The tumor-specific survival was 100%.
  • CONCLUSION: This largest randomized trial investigating treatment strategies in clinical stage I non-seminomas (AUO AH 01/94) showed the superiority of one cycle BEP over RPLND.
  • The data obtained represent the basis for a reduced chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymph Node Excision. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Bleomycin / adverse effects. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Disease-Free Survival. Etoposide / administration & dosage. Etoposide / adverse effects. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Retroperitoneal Space

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 2008 Mar;53(3):478-96 [18191324.001]
  • [Cites] BJU Int. 2006 Jul;98(1):67-9 [16831145.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9130-7 [16301596.001]
  • [Cites] Urology. 2004 Mar;63(3):556-61 [15028457.001]
  • [Cites] Actas Urol Esp. 1997 Nov-Dec;21(10):961-3 [9494159.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):2966-72 [18458040.001]
  • [Cites] J Urol. 1994 Aug;152(2 Pt 1):424-7 [8015086.001]
  • [Cites] Lancet. 1987 Aug 8;2(8554):294-8 [2886764.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1106-13 [8648364.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1513-23 [12697875.001]
  • [Cites] J Urol. 2005 Mar;173(3):824-9 [15711278.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2389-95 [15800331.001]
  • [Cites] Urology. 1994 Oct;44(4):548-52 [7941194.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1505-12 [12697874.001]
  • [Cites] Curr Treat Options Oncol. 2005 Sep;6(5):367-77 [16107240.001]
  • [Cites] Int J Androl. 1987 Feb;10(1):277-84 [2438221.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):2923-32 [8918489.001]
  • [Cites] Br J Urol. 1993 Mar;71(3):326-35 [8386580.001]
  • [Cites] J Urol. 2003 May;169(5):1710-4 [12686815.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):261-8 [9440751.001]
  • [Cites] Eur Urol. 2005 Aug;48(2):258-67; discussion 267-8 [15964134.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65 [16174857.001]
  • [Cites] J Clin Oncol. 1992 Nov;10(11):1762-8 [1403057.001]
  • [Cites] Ann Oncol. 2002 Oct;13(10 ):1616-20 [12377651.001]
  • [Cites] J Urol. 2008 Jan;179(1):163-6 [18001800.001]
  • [Cites] Eur Urol. 1990;17(2):97-106 [2155791.001]
  • [Cites] N Engl J Med. 1987 Dec 3;317(23):1433-8 [2446132.001]
  • [Cites] J Urol. 1992 Nov;148(5):1453-5; discussion 1455-6 [1279211.001]
  • (PMID = 19183929.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


16. Classen J, Souchon R, Hehr T, Bamberg M: Treatment of early stage testicular seminoma. J Cancer Res Clin Oncol; 2001 Aug;127(8):475-81
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of early stage testicular seminoma.
  • Stage I and IIA/B testicular seminoma represent approximately 45% of all testicular germ cell tumours.
  • Due to the availability of highly efficient salvage treatment, the disease-specific survival in stage I seminoma is approximately 100%, irrespective of the choice of adjuvant treatment.
  • Radiotherapy with 26 Gy to the paraaortic/paracaval lymph nodes yields excellent cure rates of 95 98% with a favourable profile of acute and late toxicity.
  • Likewise, phase-II trials with single-agent carboplatinum systemic treatment have demonstrated a rate of relapse of 3-4% on average.
  • However, carboplatinum chemotherapy has to be regarded as experimental until data of phase-III trials are available.
  • Surveillance in stage I disease is conflicted with a rate of relapse of approximately 20%.
  • In stage IIA/B seminoma, "dogleg" radiotherapy with 30 Gy and 36 Gy, respectively, provides high cure rates of 90-95%.
  • Testicular intraepithelial neoplasia (TIN) is the common precursor lesion of testicular germ cell tumours except for spermatocytic seminoma.
  • In case of TIN in a single testis or bilateral TIN, local radiotherapy with 18 Gy is recommended as standard treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Seminoma / drug therapy. Seminoma / radiotherapy. Testicular Neoplasms / drug therapy. Testicular Neoplasms / radiotherapy
  • [MeSH-minor] Biomarkers, Tumor / blood. Carboplatin / therapeutic use. Carcinoma in Situ / therapy. Chemotherapy, Adjuvant. Humans. Male. Neoplasm Staging. Population Surveillance. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11501746.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; BG3F62OND5 / Carboplatin
  • [Number-of-references] 58
  •  go-up   go-down


17. Habuchi T, Kamoto T, Hara I, Kawai K, Nakao M, Nonomura N, Kobayashi T, Ogawa O, Kamidono S, Akaza H, Okuyama A, Kato T, Miki T: Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers. Cancer; 2003 Oct 15;98(8):1635-42
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers.
  • BACKGROUND: A standard concept for the integration of surgery into the chemotherapy-based treatment of patients with advanced germ cell carcinoma has been that surgery should be avoided in patients with serum tumor markers (alpha-fetoprotein [AFP] and human chorionic gonadotropin [HCG]) that remain elevated.
  • The objective of this retrospective study was to clarify the outcome and clinical prognostic variables of salvage surgery in patients with disseminated (AJCC Stage II or III) testicular germ cell carcinoma or extragonadal germ cell carcinoma who had elevated serum markers.
  • METHODS: The authors reviewed the clinical records of 24 patients who underwent salvage surgery with elevated serum AFP and/or HCG levels after at least 3 courses of cisplatin-based, systemic chemotherapy between January, 1985 and December, 2000.
  • RESULTS: Ten of 24 patients (41.7%) were rendered free of disease and alive without disease after the surgery with or without adjuvant therapy at a median follow-up of 74 months (range, 24-207 months).
  • CONCLUSIONS: Salvage surgery in patients with high serum tumors markers resulted in long-term disease free status in approximately 40% of patients in a small subset with advanced germ cell carcinoma.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / surgery. Testicular Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Chorionic Gonadotropin / blood. Humans. Lymph Nodes / pathology. Male. Middle Aged. Prognosis. Retrospective Studies. Salvage Therapy. Survival Rate. alpha-Fetoproteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • (PMID = 14534879.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin; 0 / alpha-Fetoproteins
  •  go-up   go-down


18. Donohue JP: Evolution of retroperitoneal lymphadenectomy (RPLND) in the management of non-seminomatous testicular cancer (NSGCT). Urol Oncol; 2003 Mar-Apr;21(2):129-32
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolution of retroperitoneal lymphadenectomy (RPLND) in the management of non-seminomatous testicular cancer (NSGCT).
  • The metastatic lymphatic drainage of testis cancer to the retroperitoneum was noted clinically about a century ago.
  • The advent of platinum based combination chemotherapy has had a major impact on both the timing of and the technical requirements of RPLND.
  • Our experience with over 2500 RPLNDs in the last 3 decades is divided between low stage (I and II) and high stage (III, postchemotherapy) disease.
  • [MeSH-major] Lymph Node Excision / history. Testicular Neoplasms / history

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12856641.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Nuver J, Smit AJ, Wolffenbuttel BH, Sluiter WJ, Hoekstra HJ, Sleijfer DT, Gietema JA: The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol; 2005 Jun 1;23(16):3718-25
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer.
  • PURPOSE: The metabolic syndrome may be an important risk factor for cardiovascular disease in long-term survivors of testicular cancer (TC).
  • PATIENTS AND METHODS: We included TC patients cured by orchidectomy and cisplatin-based chemotherapy, stage I TC patients after orchidectomy only, and healthy men of comparable age.
  • Presence of the metabolic syndrome was determined using guidelines from the National Cholesterol Education Program Adult Treatment Panel III.
  • RESULTS: Eighty-six chemotherapy patients (median follow-up, 7 years) were compared with 44 stage I patients and 47 controls.
  • LH and FSH were higher, and inhibin B and total and free testosterone were lower in chemotherapy patients than controls.
  • Chemotherapy patients with the metabolic syndrome (n = 22; 26%) had a higher body mass index (BMI) pretreatment, a larger BMI increase during follow-up, lower total testosterone, and higher urinary cortisol metabolite excretion than those patients without the metabolic syndrome.
  • [MeSH-major] Follicle Stimulating Hormone / blood. Luteinizing Hormone / blood. Metabolic Syndrome X / blood. Sex Hormone-Binding Globulin / metabolism. Testicular Neoplasms / blood. Testosterone / blood
  • [MeSH-minor] Adult. Aged. Humans. Male. Middle Aged. Survivors. Time Factors

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Metabolic Syndrome.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Jun 1;23(16):3663-5 [15738543.001]
  • (PMID = 15738540.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Sex Hormone-Binding Globulin; 3XMK78S47O / Testosterone; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


20. Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, Breneman J, Qualman SJ, Wiener E, Wharam M, Lobe T, Webber B, Maurer HM, Donaldson SS: Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol; 2001 Jun 15;19(12):3091-102
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The study goal was to improve outcome in children with rhabdomyosarcoma by comparing risk-based regimens of surgery, radiotherapy (RT) and chemotherapy.
  • PATIENTS AND METHODS: Eight hundred eighty-three previously untreated eligible patients with nonmetastatic rhabdomyosarcoma entered the Intergroup Rhabdomyosarcoma Study-IV (IRS-IV) (1991 to 1997) after surgery and were randomized treatment by primary tumor site, group (1 to 3), and stage (I to III).
  • Failure-free survival (FFS) rates and survival were the end points used in comparisons between randomized groups and between patient subgroups treated on IRS-III and IRS-IV.
  • Overall, patients with embryonal tumors benefited from intensive three-drug chemotherapy in IRS-IV (3-year FFS, 83%).
  • The improvement was seen for patients with stage I or stage II/III, group 1/2 disease, many of whom received VA chemotherapy on IRS-III.
  • Patients with stage 2/3, group 3 disease had similar outcomes on IRS-III and IRS-IV.
  • CONCLUSION: VAC and VAI or VIE with surgery (with or without RT), are equally effective for patients with local or regional rhabdomyosarcoma and are more effective for embryonal tumors than therapies used previously.
  • Younger patients with group 1 paratesticular embryonal tumors and all patients with group 1/2 orbit or eyelid tumors can usually be cured with VA chemotherapy along with postoperative RT for group 2 disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Radiotherapy / methods. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy / methods. Disease-Free Survival. Dose Fractionation. Eyelid Neoplasms / mortality. Eyelid Neoplasms / pathology. Eyelid Neoplasms / therapy. Female. Humans. Infant. Male. Orbital Neoplasms / mortality. Orbital Neoplasms / pathology. Orbital Neoplasms / therapy. Prognosis. Retrospective Studies. Survival Rate. Testicular Neoplasms / mortality. Testicular Neoplasms / pathology. Testicular Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11408506.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-13539; United States / NCI NIH HHS / CA / CA-24507; United States / NCI NIH HHS / CA / CA-29139; United States / NCI NIH HHS / CA / CA-30138; United States / NCI NIH HHS / CA / CA-30969
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


21. Kusumakumary P, Mathew BS, Hariharan S, Priyakumari T, Rajan B: Testicular germ cell tumors in prepubertal children. Pediatr Hematol Oncol; 2000 Jan-Feb;17(1):105-11
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular germ cell tumors in prepubertal children.
  • Pediatric testicular germ cell tumors are rare.
  • All were staged according to the Pediatric Oncology Group/Children's Cancer Study Group staging system.
  • Seven patients had stage III disease.
  • Histologically, 9 patients had pure endodermal sinus tumor, 1 had endodermal sinus tumor with embryonal carcinoma, 1 had embryonal carcinoma alone, 2 had immature teratoma, and 2 had mature teratoma.
  • All others received chemotherapy with cisplatin, bleomycin, and vinblastine.
  • [MeSH-major] Germinoma. Testicular Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Child, Preschool. Cisplatin / therapeutic use. Humans. Infant. Male. Survival Analysis. Vinblastine / therapeutic use

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10689721.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


22. Maldonado-Valadez R, Schilling D, Anastasiadis AG, Sturm W, Stenzl A, Corvin S: Post-chemotherapy laparoscopic retroperitoneal lymph-node dissection in testis cancer patients. J Endourol; 2007 Dec;21(12):1501-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-chemotherapy laparoscopic retroperitoneal lymph-node dissection in testis cancer patients.
  • BACKGROUND AND PURPOSE: Retroperitoneal lymph node dissection (RPLND) is still the most sensitive and specific method for the detection of malignant tumor and mature teratoma in stage II nonseminomatous testicular carcinoma after chemotherapy.
  • In this study, we describe our experiences with laparoscopic RPLND for stage II testicular carcinoma after chemotherapy.
  • METHODS: Sixteen patients underwent 17 laparoscopic RPLND after chemotherapy for clinical stage IIA-III nonseminomatous testicular cancer.
  • Patients with post-chemotherapy residual masses >1 cm and normalization of tumor markers were considered for the procedure.
  • Our dissection field included the resection of the residual tumor as well as the ipsilateral template.
  • Operative time ranged from 125 to 370 minutes (mean 240 +/- 56 min).
  • No transfusions were required, and no intra- or postoperative complications occurred because of the procedure.
  • A bleomycin-induced interstitial pneumonia developed in one patient.
  • CONCLUSION: Laparoscopic RPLND after chemotherapy is a feasible and oncologically safe procedure.
  • However, the technique is challenging and should only be performed in selected patients with low residual tumor volume.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18186691.001).
  • [ISSN] 0892-7790
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


23. Spiess PE, Brown GA, Liu P, Tannir NM, Tu SM, Evans JG, Czerniak B, Kamat AM, Pisters LL: Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer; 2006 Oct 1;107(7):1483-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer.
  • BACKGROUND: The management of metastatic nonseminomatous germ cell tumors (NSGCT) frequently consists of systemic chemotherapy followed by retroperitoneal lymph node dissection (PC-RPLND).
  • METHODS: Between 1980 and 2003, 236 patients with clinical Stage IIA-III NSGCT underwent PC-RPLND.
  • Their medical records were retrospectively reviewed for pertinent clinical and treatment-related outcomes.
  • RESULTS: The median age of patients at diagnosis was 28 years, with all patients receiving systemic chemotherapy (median of 5 cycles) before RPLND.
  • Predictors of poorer recurrence-free survival (RFS) included advanced clinical stage (IIC-III, P = .001) and presence of viable tumor in the RPLND specimen (P = .03).
  • CONCLUSIONS: In patients undergoing PC-RPLND, preoperative tumor markers and the occurrence of postoperative complications or recurrence are predictive of poorer DSS.
  • Advanced clinical stage and viable tumor in the surgical specimen predict worse RFS.
  • [MeSH-major] Biomarkers, Tumor / blood. Lymph Node Excision. Neoplasm Recurrence, Local / mortality. Testicular Neoplasms / mortality. Testicular Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Disease-Free Survival. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retroperitoneal Space. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16944541.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


24. Mosharafa AA, Foster RS, Bihrle R, Koch MO, Ulbright TM, Einhorn LH, Donohue JP: Does retroperitoneal lymph node dissection have a curative role for patients with sex cord-stromal testicular tumors? Cancer; 2003 Aug 15;98(4):753-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does retroperitoneal lymph node dissection have a curative role for patients with sex cord-stromal testicular tumors?
  • BACKGROUND: Sex cord-stromal tumors account for < 5% of all adult testicular tumors, and 10% are malignant.
  • METHODS: Reviewing the Indiana University testis cancer registry revealed 17 patients who underwent RPLND for sex cord-stromal tumors.
  • The data examined included clinical and pathologic stage, surgical procedure, additional therapy received, and outcome.
  • RESULTS: Pathology included Leydig tumors in six patients, Sertoli tumors in four patients, sex cord-stromal tumors in five patients, a granulosa cell tumor in one patient, and a poorly differentiated non-germ cell tumor in one patient.
  • Clinical stage at surgery was Stage I in nine patients and Stage IIA-IIIA in eight patients.
  • Nine patients had pathologic Stage I tumors, and the remaining eight patients and had pathologic Stage IIB-IIIA tumors.
  • Of the eight patients with Stage II-III disease, six patients eventually died of metastatic disease despite additional radiotherapy and/or chemotherapy.
  • Although the therapeutic role of RPLND in patients with small-volume metastatic retroperitoneal tumors is unclear, RPLND remains an option to be performed immediately after orchiectomy, especially in patients who have tumors with malignant features and/or small-volume metastatic disease.
  • [MeSH-major] Lymph Node Excision. Sex Cord-Gonadal Stromal Tumors / surgery. Testicular Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • (PMID = 12910519.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Zouhair A, Weber D, Belkacémi Y, Ketterer N, Dietrich PY, Villà S, Scandolaro L, Bieri S, Studer G, Delacretaz F, Girardet C, Mirimanoff RO, Ozsahin M, Rare Cancer Network: Outcome and patterns of failure in testicular lymphoma: a multicenter Rare Cancer Network study. Int J Radiat Oncol Biol Phys; 2002 Mar 1;52(3):652-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and patterns of failure in testicular lymphoma: a multicenter Rare Cancer Network study.
  • PURPOSE: To assess the outcome and patterns of failure in patients with testicular lymphoma treated by chemotherapy (CT) and/or radiation therapy (RT).
  • METHODS AND MATERIALS: Data from a series of 36 adult patients with Ann Arbor Stage I (n = 21), II (n = 9), III (n = 3), or IV (n = 3) primary testicular lymphoma, consecutively treated between 1980 and 1999, were collected in a retrospective multicenter study by the Rare Cancer Network.
  • Full staging workup (chest X-ray, testicular ultrasound, abdominal ultrasound, and/or thoracoabdominal computer tomography, bone marrow assessment, full blood count, lactate dehydrogenase, and cerebrospinal fluid evaluation) was completed in 18 (50%) patients.
  • External RT was delivered to scrotum alone (n = 12) or testicular, iliac, and para-aortic regions (n = 8).
  • The median RT dose was 31 Gy (range: 20-44 Gy) in a median of 17 fractions (10-24), using a median of 1.8 Gy (range: 1.5-2.5 Gy) per fraction.
  • No testicular, iliac, or para-aortic relapse was observed in patients receiving RT to these regions.
  • In univariate analyses, statistically significant factors favorably influencing the outcome were early-stage and combined modality treatment.
  • Multivariate analysis revealed that the most favorable independent factors predicting the outcome were younger age, early-stage disease, and combined modality treatment.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Testicular Neoplasms / drug therapy. Testicular Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Orchiectomy. Prednisolone / administration & dosage. Prognosis. Radiotherapy Dosage. Recurrence. Retrospective Studies. Treatment Failure. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11849786.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


26. Muramaki M, Hara I, Miyake H, Yamada Y, Kawabata G, Kamidono S: Advances in the management of non-seminomatous germ cell tumors during the cisplatin era: a single-institution experience. Int J Urol; 2004 Sep;11(9):768-73
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the management of non-seminomatous germ cell tumors during the cisplatin era: a single-institution experience.
  • BACKGROUND: The objectives of the present study were to review chronological changes in the long-term survival of patients with non-seminomatous germ cell tumor (NSGCT) who were treated at a single institution after the introduction of cisplatin-based combination chemotherapy.
  • To evaluate chronological changes in treatment outcome between 1978 and 2001, data were analyzed according to the timing of initial treatment in two consecutive 12-year periods.
  • Patients were classified according to criteria of both the Japanese Urological Association (JUA classification) and the International Germ Cell Cancer Collaborative Group (IGCCCG classification).
  • A significant improvement in survival was found in the patients with stage III disease, according to the JUA classification, and in the patients with poor-risk disease, according to the IGCCCG classification (P = 0.004 and 0.05, respectively).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Germinoma / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Follow-Up Studies. Humans. Male. Neoplasm Staging. Retrospective Studies. Risk Factors. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15379942.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


27. Gori S, Porrozzi S, Roila F, Gatta G, De Giorgi U, Marangolo M: Germ cell tumours of the testis. Crit Rev Oncol Hematol; 2005 Feb;53(2):141-64
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germ cell tumours of the testis.
  • Cancer of the testis is a relatively rare disease, accounting for about 1% of all cancers in men.
  • Cryptorchidism is the only confirmed risk factor for testicular germ cell tumour.
  • Any nodular, hard, or fixed area discovered in the testis, must be considered neoplastic until proved otherwise.
  • The appropriate surgical procedure to make the diagnosis is a radical orchidectomy through an inguinal incision.
  • Many GCT produce tumoural markers (AFP, HCG, LDH), who are useful in the diagnosis and staging of disease; to monitor the therapeutic response and to detect tumour recurrence.
  • In 1997 a prognostic factor-based classification for the metastatic germ cell tumours was developed by the IGCCCG: good, intermediate and poor prognosis, with 5-year survival of 91, 79 and 48%, respectively.
  • GCT of the testis is a highly table, often curable, cancer.
  • Germ cell testicular cancers are divided into seminoma and non-seminoma types for treatment planning because seminomatous testicular cancers are more sensitive to radiotherapy.
  • For patients with low-stage disease, the cure approaches 100%.
  • For patients with non-seminoma tumours, the cure rate is >95% in stages I and II; it is approximately 70% with standard chemotherapy and resection of residual disease, if necessary, in stages III and IV.
  • [MeSH-major] Germinoma. Testicular Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661565.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 189
  •  go-up   go-down


28. Mazloom A, Fowler N, Medeiros LJ, Iyengar P, Horace P, Dabaja BS: Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience. Leuk Lymphoma; 2010 Jul;51(7):1217-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience.
  • The purpose of this study was to assess the clinicopathologic characteristics and outcomes in patients with diffuse large B-cell lymphoma (DLBCL) of the testis, and to assess the impact of changes in the therapeutic approach that have occurred over the years.
  • Factors analyzed included: age, clinical stage, B-symptoms, serum levels of lactate dehydrogenase (LDH), beta(2)-microglobulin, treatment received, and outcome.
  • Immunophenotypic data were available for 43 cases, all of which showed B-cell lineage.
  • On univariate analysis, stages III and IV (p = 0.042), elevated serum LDH (p = 0.014), B-symptoms (p = 0.003), and high-intermediate or high International Prognostic Index (IPI) score (p = 0.010) were associated with a significantly decreased overall survival (OS) and progression-free survival (PFS).
  • The 5-year OS and PFS for patients after 2000, treated predominantly with R-CHOP, intrathecal chemotherapy (ITC), and scrotal radiotherapy (RT), were 86.6% and 59.3%, respectively.
  • This is compared to 56.3% and 51.7%, respectively, for patients treated between 1977 and 1999 with doxorubicin based chemotherapy without rituximab, who were not uniformly treated with ITC.
  • Patients treated prior to 1977 had an OS and PFS of 15.4% and 15.4%, respectively, and were not treated with doxorubicin based chemotherapy or ITC (p = 0.019 for OS and p = 0.138 for PFS).
  • Advanced stage, elevated serum LDH, B-symptoms, and high IPI are poor prognostic markers.
  • R-CHOP based chemotherapy with intrathecal chemotherapy and scrotal RT is associated with an improved OS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Prednisone / administration & dosage. Radiotherapy Dosage. Rituximab. Survival Rate. Treatment Outcome. Vincristine / administration & dosage. Young Adult. beta 2-Microglobulin / blood

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2010 Jul;51(7):1159-60 [20497004.001]
  • (PMID = 20443676.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / beta 2-Microglobulin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; VB0R961HZT / Prednisone
  •  go-up   go-down


29. Jun HJ, Kim WS, Yang JH, Yi SY, Ko YH, Lee J, Jung CW, Kang SW, Park K: Orbital infiltration as the first site of relapse of primary testicular T-cell lymphoma. Cancer Res Treat; 2007 Mar;39(1):40-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital infiltration as the first site of relapse of primary testicular T-cell lymphoma.
  • A 43-year-old male presented with a painless left testicular mass.
  • The pathologic diagnosis of the radical orchiectomy specimen was peripheral T-cell lymphoma, unspecified (PTCL-u).
  • According to the Ann Arbor staging system, his initial stage was III because of the right nasopharyngeal involvement.
  • After first-line chemotherapy with four courses of the CHOP regimen and this was followed by involved-field radiotherapy, he achieved complete remission.
  • Although the patient received intensive chemotherapy with autologous hematopoietic stem cell transplantation, he ultimately died of leptomeningeal seeding.
  • Because both the central nervous system (CNS) and the orbit are sanctuary sites for chemotherapy, orbital infiltration of lymphoma should prompt physicians to evaluate involvement of the CNS and to consider performing prophylactic intrathecal chemotherapy as a treatment option.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 1999 Nov;106(11):2109-20 [10571346.001]
  • [Cites] Eur J Cancer. 1994;30A(12):1760-4 [7880601.001]
  • [Cites] Am J Surg Pathol. 1994 Apr;18(4):376-90 [8141430.001]
  • [Cites] Histopathology. 1989 Aug;15(2):147-56 [2777217.001]
  • [Cites] Br J Urol. 1984 Oct;56(5):525-30 [6398719.001]
  • [Cites] Arch Ophthalmol. 1984 Mar;102(3):399-402 [6608342.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):154-61 [10618618.001]
  • (PMID = 19746228.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2739356
  • [Keywords] NOTNLM ; Eye neoplasm / Non-Hodgkin's lymphoma / T cell lymphoma / Testes
  •  go-up   go-down


30. Sun XF, Yang QY, Zhen ZJ, Xia Y, Huang ZH, Ling JY: [Treatment outcome of children and adolescents with germ cell tumor after combined therapy---a report of 44 cases]. Ai Zheng; 2006 Dec;25(12):1529-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment outcome of children and adolescents with germ cell tumor after combined therapy---a report of 44 cases].
  • BACKGROUND & OBJECTIVE: The overall survival rate of children and adolescents with germ cell tumor is more than 75% after adopting combined therapy.
  • However, the prognosis varies with stage, pathologic type, and primary tumor site.
  • This study was to analyze the clinical characteristics and treatment outcome of children and adolescents with germ cell tumor, and to investigate the prognostic factors and therapeutic strategy.
  • METHODS: Clinical characteristics, treatment outcome, and prognostic factors of 44 children and adolescents with germ cell tumor, treated in Cancer Center of Sun Yat-sen University from Jan.
  • RESULTS: Of the 44 patients, 25 received adjuvant chemotherapy after operation; 1 received operation alone; 18 received induction chemotherapy.
  • Of the 18 patients, 7 received tumor resection after chemotherapy; 2 patients with primary mediastinal chorioepithelioma with multiple metastases received radiotherapy on residual disease after chemotherapy; 1 patient with postoperative abdominal metastasis and 1 with postoperative lung metastasis achieved complete remission after chemotherapy; 1 patient with mediastinal sinus tumor achieved partial remission after chemotherapy; 6 had poor response to chemotherapy and died of disease progression.
  • Chemotherapy-treated patients received platinum-containing regimens for 2-7 cycles.
  • The 3-year survival rate was 100% for stage I-II patients, 83.3% for stage III patients, 65.6% for stage IV patients, and 66.7% for relapsed patients.
  • For previously untreated patients, the 3-year survival rate was 96.0% for gonadal germ cell tumor patients and 61.0% for extragonadal germ cell tumor patients.
  • CONCLUSION: Surgery combined with platinum-containing chemotherapy can improve efficacy and survival of children and adolescents with germ cell tumor.
  • For the patients with stage IV, relapsed, and metastatic tumors, novel therapeutic regimens with increased dose intensity need further investigation.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / surgery
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Chemotherapy, Adjuvant. Child. Child, Preschool. Cisplatin / therapeutic use. Endodermal Sinus Tumor / drug therapy. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / surgery. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Infant. Male. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / surgery. Neoplasm Recurrence, Local. Neoplasm Staging. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Remission Induction. Survival Rate. Teratoma / drug therapy. Teratoma / pathology. Teratoma / surgery. Testicular Neoplasms / drug therapy. Testicular Neoplasms / pathology. Testicular Neoplasms / surgery. Treatment Outcome. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17166380.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol; COB protocol
  •  go-up   go-down


31. Mosharafa AA, Foster RS, Koch MO, Bihrle R, Donohue JP: Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. J Urol; 2004 May;171(5):1839-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer.
  • PURPOSE: Post-chemotherapy retroperitoneal lymph node dissection (PC RPLND) is a tool in the management of testis cancer.
  • Our impression has been that the short-term morbidity of standard PC RPLND has diminished with time.
  • Therefore, we attempted to verify this hypothesis by evaluating the morbidity of the procedure in 2 comparable groups of patients from 2 different periods.
  • MATERIALS AND METHODS: We compared 150 patients who underwent post-chemotherapy RPLND between July 2000 and July 2002 to 79 patients who underwent the same procedure between 1990 to 1992.
  • All patients had clinical stage II-III testis cancer and had received 3 to 4 courses of standard platinum based chemotherapy before surgery.
  • RESULTS: The 2 groups were comparable regarding preoperative clinical stage, patient characteristics and postoperative pathological findings.
  • CONCLUSIONS: With time morbidity and hospital stay after standard PC RPLND have decreased.
  • Therefore, comparing newer surgical techniques to historical controls is inappropriate since differences may not actually represent the technical advances of the newer procedure.
  • [MeSH-major] Lymph Node Excision / adverse effects. Testicular Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15076289.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Tavolini IM, Norcen M, Oliva G, Nigro F, Benedetto G, Mazzariol C, Bassi P: [Caval involvement in advanced-stage non-seminoma testicular tumors: surgical strategy and long-term results]. Arch Ital Urol Androl; 2002 Jun;74(2):69-76
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Caval involvement in advanced-stage non-seminoma testicular tumors: surgical strategy and long-term results].
  • OBJECTIVES: The involvement of vena cava by residual masses after cytoreductive chemotherapy for bulky metastatic germ cell tumors is a rare but possible event.
  • It could ensue by tumor invasion of the inferior vena cava (IVC), venous or neoplastic thrombosis, or by close adherence and encasement of IVC by scar tissue containing fibrosis or cancer; it usually occurs in right testicular neoplasms.
  • In this study we evaluated a group of nine over 86 patients who underwent IVC (and possibly aortic) surgery for post-chemotherapy residual masses and we assessed long term oncological and functional efficacy of the procedure.
  • MATERIALS AND METHODS: Between 1980 and 1997, 86 patients underwent retroperitoneal lymphadenectomy (RPLND) after induction or additional salvage chemotherapy.
  • A subgroup of nine patients, all with primary tumors of the right testis in stage II C to III, showed evidence of caval involvement, four had caval thrombosis, seven exhibited caval invasion; in one case the IVC was displaced and compressed with no clear evidence of infiltration.

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12161940.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ITA
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


33. Choo R, Sandler H, Warde P, Hruby G, DeBoer G: Survey of radiation oncologists: practice patterns of the management of stage I seminoma of testis in Canada and a selected group in the United States. Can J Urol; 2002 Apr;9(2):1479-85
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survey of radiation oncologists: practice patterns of the management of stage I seminoma of testis in Canada and a selected group in the United States.
  • OBJECTIVE: To evaluate practice patterns of the management of stage I seminoma of testis in Canada and a selected group in the United States.
  • RT to the para-aortic and ipsilateral pelvis ('dog-leg'), 4. single-agent chemotherapy), the order of first preference was option 1 (44%), 2 (42%), and 3 (14%) for patients who wish to preserve fertility.
  • The commonest dose-fractionation schedule was 25 Gy/20 fractions (68%).
  • Others included 25 Gy/15 f (15%), and 25.5 Gy/17 f (4%).
  • Twenty-nine percent reduced RT volume from the 'dog-leg' to the para-aortic region as the result of MRC Phase III study published in 1999.
  • CONCLUSION: There are significant variations in the practice pattern of the management of stage I seminoma of testis among radiation oncologists in Canada and a selected group in the United States.
  • [MeSH-major] Practice Patterns, Physicians' / statistics & numerical data. Seminoma / therapy. Testicular Neoplasms / therapy

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Can J Urol. 2002 Apr;9(2):1476 [12010591.001]
  • (PMID = 12010592.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


34. Patterson H, Norman AR, Mitra SS, Nicholls J, Fisher C, Dearnaley DP, Horwich A, Mason MD, Huddart RA: Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. Radiother Oncol; 2001 Apr;59(1):5-11
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone.
  • PURPOSE: To assess the results of treatment in 33 patients with stage IIA/B seminoma who were treated with carboplatin and radiotherapy (RT) between January 1989 and December 1996.
  • With a median follow-up of 4 years (range 2-70 months) 2/33 patients treated with chemotherapy and RT have relapsed, 5-year relapse free survival (RFS) = 96.9% (95% confidence interval (CI) 72.9-99.4%), and one patient has died of progressive disease, 5-year overall survival (OS) = 96.7%.
  • For stage IIA, 1/14 patients treated with chemotherapy and RT have relapsed, 5-year RFS = 92.3%, compared with 5/34 treated with infra-diaphragmatic RT alone 5-year, RFS = 84.9% (P = 0.527).
  • For stage IIB, 1/19 patients relapsed (at 69 months) following chemotherapy and RT (5-year RFS = 100%), whereas 8/27 relapsed following infra-diaphragmatic RT alone, 5-year RFS = 69.4% (P = 0.0595).
  • CONCLUSION: Infradiaphragmatic RT alone cures the majority of patients with stage II seminoma, but the relapse rate remains high particularly for patients with stage IIB disease.
  • As compared with historical controls, carboplatin with RT appears to reduce the relapse rate in stage II seminoma with minimal additional toxicity and the results approach statistical significance for stage IIB patients.
  • Confirmation would require a phase III randomized comparison.
  • [MeSH-major] Carboplatin / administration & dosage. Radiotherapy / methods. Seminoma / drug therapy. Seminoma / radiotherapy. Testicular Neoplasms / drug therapy. Testicular Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiation Dosage. Reference Values. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Radiother Oncol. 2001 Apr;59(1):1-3 [11295199.001]
  • (PMID = 11295200.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin
  •  go-up   go-down


35. Matsunuma H, Ono Y, Hattori R, Gotoh M, Yoshino Y, Ohshima S: [Laparoscopic retroperitoneal lymphnode dissection for testicular cancer: Nagoya experience]. Hinyokika Kiyo; 2003 Jul;49(7):377-80
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic retroperitoneal lymphnode dissection for testicular cancer: Nagoya experience].
  • Three patients with stage I disease and 3 patients with stage III disease were treated with laparoscopic retroperitoneal lymphnode dissection.
  • The procedure was completed successfully on all 6 patients.
  • The average operative time was 3.4 hours for 3 patients with stage I disease and 4.4 hours for 3 patients with stage III disease treated with prior chemotherapy.
  • Laparoscopic retroperitoneal lymphnode dissection will be a useful technique for management of testicular cancer.
  • [MeSH-major] Laparoscopy. Lymph Node Excision / methods. Seminoma / surgery. Testicular Neoplasms / surgery

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12968476.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


36. Tsukamoto T, Fukui I: [Treatment and prognosis of testicular seminoma]. Gan To Kagaku Ryoho; 2000 Apr;27(4):516-21
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment and prognosis of testicular seminoma].
  • Although testicular germ cell tumor is a relatively uncommon disease, it is a relatively common type of malignant tumor among young men.
  • Seminoma accounts for approximately 50% of all germ cell testicular tumors.
  • Since the vast majority of patients with seminoma present with early-stage disease and the disease responds well to treatment, almost all of the patients are cured.
  • Patients who have stage I disease without obvious metastatic lesions have two treatment options, surveillance or adjuvant retroperitoneal radiotherapy, following inguinal orchiectomy.
  • Stage IIA disease with a relatively small retroperitoneal lymph node metastasis is generally treated by retroperitoneal radiation therapy, although systemic chemotherapy with carboplatin is an alternative treatment.
  • For patients with bulky retroperitoneal lymph node or distant metastases (stage IIB, III), systemic chemotherapy including cisplatin and etoposide appears to be the standard approach.
  • Recently, 85% to 90% of patients with stage III disease are cured.
  • Thus, the current therapeutic goal is cure of the disease with the minimum of treatment sequelae.
  • [MeSH-major] Seminoma / therapy. Testicular Neoplasms / therapy

  • Genetic Alliance. consumer health - Seminoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10790992.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Number-of-references] 34
  •  go-up   go-down


37. Song Y, Yang L, Ma JH, Liu XF, Wang JW: [Long-term outcome of testicular seminoma in 294 patients]. Zhonghua Zhong Liu Za Zhi; 2008 Aug;30(8):626-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term outcome of testicular seminoma in 294 patients].
  • OBJECTIVE: To analyze the correlation of long-term survival with the treatment strategies in patients with testicular seminoma.
  • METHODS: Clinical data of 294 patients with testicular seminoma treated in our hospital between 1959 and 2004 were collected and analyzed.
  • Among them, 260 were in stage I disease, 16 in stage II, and 18 in stage III.
  • The patients were treated by surgical resection plus chemotherapy and/or radiotherapy.
  • The major prognostic factor was found to be clinical stage.
  • The patients with adjuvant chemotherapy after orchiectomy had better 10-year survival than the patients without (97.5% vs. 79.2%, P = 0.001).
  • For stage II/III patients, the patients with chemotherapy and the patients with chemotherapy plus radiotherapy had a similar progression-free survival (PFS) and overall survival (OS) (P > 0.05).
  • CONCLUSION: Testicular seminoma is sensitive to chemotherapy and radiotherapy, and a good cure rate can still be achieved in the relapsed patients with a salvage treatment.
  • Therefore, wide excision and long-term chemotherapy should be avoided in order to maintain the quality of life in those patients.
  • [MeSH-major] Neoplasm Recurrence, Local / therapy. Orchiectomy / methods. Seminoma / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Salvage Therapy. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Seminoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102945.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


38. Wehrschütz M, Stöger H, Ploner F, Hofmann G, Wolf G, Höfler G, Krippl P, Samonigg H: Seminoma metastases mimicking primary pancreatic cancer. Onkologie; 2002 Aug;25(4):371-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seminoma metastases mimicking primary pancreatic cancer.
  • BACKGROUND: A case of seminoma clinical stage III, arising from the right testis and mimicking a primary pancreatic malignancy is reported.
  • Abdominal CT scan showed a tumor in the head of the pancreas and multiple pathologically enlarged peripancreatic lymph nodes.
  • Further laboratory findings showed an elevation of the human placental alkaline phosphatase (HPLAP) and urological examination revealed a suspect right testis.
  • The patient underwent castration of the right testis and histopathological examination confirmed a seminoma.
  • 4 cycles of chemotherapy including cisplatinum, etoposide and bleomycin led into complete response that is still ongoing.
  • It provides an example of the possibility of an uncommon clinical appearance of seminoma metastases and again underlines the importance of exact radiological and histopathological examination to distinguish between curable and incurable tumor.
  • [MeSH-major] Pancreatic Neoplasms / secondary. Seminoma / secondary. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Pancreas / pathology. Tomography, X-Ray Computed


39. Subramanian VS, Nguyen CT, Stephenson AJ, Klein EA: Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer. Urol Oncol; 2010 Sep-Oct;28(5):504-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer.
  • OBJECTIVE: Treatment decisions regarding the use of retroperitoneal lymph node dissection (RPLND) for low-stage and advanced testicular cancer may be influenced by the morbidity of the procedure.
  • We sought to compare the complication profile of primary (P-) and post-chemotherapy (PC-) RPLND using a standardized complication grading scale.
  • Major postoperative complications (grades III-V) were observed in 3 (3%) P-RPLND and 8 (8%) PC-RPLND patients (P = 0.15), including 1 fatal pulmonary embolus in a PC-RPLND patient.
  • PC-RPLND was associated with significantly greater operative times, blood loss, and transfusion rates (P < 0.001).
  • Compared with PC-RPLND after first-line chemotherapy for advanced NSGCT, there were no significant differences in perioperative outcomes for PC-RPLND performed in other settings.
  • The safe morbidity profile of RPLND performed by fellowship-trained urologic oncologists should be considered during treatment decision-making for low-stage and advanced testicular cancer.
  • [MeSH-major] Lymph Node Excision / adverse effects. Testicular Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Ejaculation. Humans. Intraoperative Complications / epidemiology. Male. Middle Aged. Postoperative Complications / epidemiology. Retroperitoneal Space. Seminoma / surgery

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19097812.001).
  • [ISSN] 1873-2496
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Feldman DR, Bosl GJ: Treatment of stage I seminoma: is it time to change your practice? J Hematol Oncol; 2008;1:22
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of stage I seminoma: is it time to change your practice?
  • At the plenary session of the 2008 annual meeting of the American Society of Clinical Oncology, updated results were presented from a large randomized phase III trial comparing adjuvant radiation therapy (RT) and one cycle of Carboplatin for the adjuvant treatment of Stage I seminoma.
  • In this editorial, the trial's design, statistics, toxicity, and length of follow-up are discussed within the context of historical treatments of this disease.
  • A decrease in second testicular germ cell tumors was observed, but was equivalent to the increase in relapse rate.
  • Surveillance-based strategies, including risk-adapted policies that limit RT to patients with the greatest likelihood of relapse remain prudent at this time.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Seminoma / drug therapy. Seminoma / radiotherapy. Testicular Neoplasms / drug therapy. Testicular Neoplasms / radiotherapy
  • [MeSH-minor] Clinical Trials, Phase III as Topic. Humans. Male. Neoplasm Staging. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Nov 15;20(22):4448-52 [12431967.001]
  • [Cites] J Urol. 2008 Aug;180(2):577-81; discussion 581-2 [18554661.001]
  • [Cites] Lancet. 1981 Oct 31;2(8253):970-3 [6117736.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):598-606 [8386751.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1844-52 [9164194.001]
  • [Cites] Lancet. 2005 Jul 23-29;366(9482):293-300 [16039331.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65 [16174857.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8717-23 [16260698.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):467-75 [16421423.001]
  • [Cites] Urol Oncol. 2006 May-Jun;24(3):180-3 [16678046.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4370-8 [17906202.001]
  • [Cites] Urology. 2007 Oct;70(4):777-80 [17991554.001]
  • [Cites] N Engl J Med. 2007 Nov 29;357(22):2277-84 [18046031.001]
  • [Cites] Ann Oncol. 2008 Mar;19(3):443-7 [18048383.001]
  • [Cites] Ann Oncol. 2003 Jun;14(6):867-72 [12796024.001]
  • (PMID = 18992162.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ PMC2588624
  •  go-up   go-down


41. Spiess PE, Pisters LL, Liu P, Pettaway CA, Kamat AM, Gomez JA, Tannir NM: Malignant transformation of testicular teratoma: a chemoresistant phenotype. Urol Oncol; 2008 Nov-Dec;26(6):595-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of testicular teratoma: a chemoresistant phenotype.
  • RESULTS: Two patients presented with clinical stage I disease in which malignant transformation occurred within the primary testis tumor (rhabdomyosarcoma in 1 and adenocarcinoma in 1).
  • No viable tumor was identified in the specimen, and both patients were alive without disease at 16 months follow-up.
  • Of the remaining 7 patients, the clinical stages were IIA (N = 1), IIB (N = 3), and III (N = 3), and all were treated with chemotherapy followed by RPLND.
  • Following preoperative chemotherapy, a significant radiologic response (defined as more than a 25% reduction in maximum tumor circumferential diameter) was demonstrated in 1 patient, and normalization of serum tumor markers was demonstrated in 6.
  • CONCLUSIONS: In our experience, MTT is significantly resistant to current chemotherapeutic regimens, as demonstrated by its poor radiologic response to treatment.
  • Alternative therapeutic strategies targeted to MTT are thus needed.
  • [MeSH-major] Teratoma / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Drug Resistance, Neoplasm. Humans. Lymph Node Excision. Male. Neoplasm Staging. Retroperitoneal Space

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2781-8 [15837993.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 1998 Jun;89(6):622-6 [9666691.001]
  • [Cites] Semin Urol Oncol. 1998 May;16(2):65-71 [9649229.001]
  • [Cites] J Urol. 1998 Mar;159(3):859-63 [9474169.001]
  • [Cites] Scand J Urol Nephrol. 2003;37(2):177-8 [12745729.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):860-3 [2990657.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4285-91 [14645417.001]
  • [Cites] J Urol. 1998 Jan;159(1):133-8 [9400455.001]
  • [CommentIn] Urol Oncol. 2009 Mar-Apr;27(2):218; author reply 218-9 [19285238.001]
  • (PMID = 18367105.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS610854; NLM/ PMC4121060
  •  go-up   go-down


42. Bhala N, Coleman JM, Radstone CR, Horsman JM, George J, Hancock BW, Hatton MQ, Coleman RE: The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients. Clin Oncol (R Coll Radiol); 2004 Feb;16(1):40-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients.
  • AIMS: The survival of germ-cell tumours (GCT) was transformed after the introduction of cisplatin-based therapy.
  • Previous trials have indicated BEP (bleomycin, etoposide and cisplatin) as the optimum treatment, although some centres including our own advocate the use of the alternating regimen POMB-ACE (cisplatin, vincristine, methotrexate, bleomycin and dactinomycin, cyclophosphamide and etoposide) for men with intermediate or poor prognosis disease.
  • We analysed the survival and management of GCT patients treated at a specialist cancer centre in relation to internationally recognised prognostic groupings.
  • MATERIALS AND METHODS: We retrieved patient information using the Trent Testicular Tumour Registry and supplemented it with information from patient notes.
  • This included all patients with Royal Marsden Hospital Stage II, III and IV disease and patients with stage I disease at diagnosis with raised markers or subsequent relapse.
  • We compared the efficacy and toxicity of the BEP and POMB-ACE chemotherapy regimens, and assessed relapse-free and overall survival.
  • RESULTS: We identified 178 non-seminomatous germ cell tumours (NSGCT) and 71 seminoma patients.
  • Overall survival was similar to the International Germ Cell Cancer Collaborative Group (IGCCCG) classification for the good (95% vs 92%) and intermediate groups (82% vs 80%).
  • This may reflect use of the POMB-ACE chemotherapy regimen as opposed to standard BEP regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinoma / drug therapy. Germinoma / pathology. Neoplasm Staging. Registries / statistics & numerical data. Testicular Neoplasms / drug therapy. Testicular Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14768754.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; BEP protocol; PROMACE protocol
  •  go-up   go-down


43. Sato S, Tanaka T, Takahashi A, Sasai M, Kitamura H, Masumori N, Tsukamoto T: Late recurrence and second primary malignancy among 139 patients with germ cell tumors: long-term outcome of the disease in a single-center experience. Jpn J Clin Oncol; 2010 Feb;40(2):157-62
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late recurrence and second primary malignancy among 139 patients with germ cell tumors: long-term outcome of the disease in a single-center experience.
  • OBJECTIVE: We retrospectively evaluated long-term oncological outcomes in patients with germ cell tumors (GCTs) primarily treated at our institution and assessed late recurrence and second primary malignancies.
  • METHODS: This study included a total of 139 males with newly diagnosed GCTs of the testis or extragonadal origin who received treatment, including surgery, chemotherapy and radiation therapy, at our hospital between 1980 and 2005.
  • RESULTS: In patients with seminoma, 5-year progression-free survival and cause-specific survival rates were 87.2% and 100% for Stage I, 88.9% and 100% for Stage II, and 50.0% and 50.0% for Stage III, respectively, whereas in those with non-seminomatous GCTs, they were 79.1% and 96.3% for Stage I, 89.5% and 89.4% for Stage II, and 85.7% and 78.4% for Stage III, respectively.
  • Late recurrence was found in five (3.6%) patients and all of them responded to salvage treatment and achieved disease-free status.
  • CONCLUSIONS: Late recurrence was successfully managed with appropriate treatments, although its incidence was not negligible.
  • Periodic follow-up may be necessary for >5 years in patients with GCTs for early detection of late recurrence.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Second Primary / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Seminoma / pathology. Seminoma / therapy. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Aug 1;95(3):520-30 [12209744.001]
  • [Cites] J Clin Oncol. 2008 Dec 1;26(34):5524-9 [18936477.001]
  • [Cites] Urol Clin North Am. 2003 Nov;30(4):803-17 [14680316.001]
  • [Cites] N Engl J Med. 1987 Jun 4;316(23):1435-40 [2437455.001]
  • [Cites] Lancet. 1991 Aug 10;338(8763):359-63 [1713639.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):283-92 [7799032.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1170-6 [7537800.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 1;89(19):1429-39 [9326912.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3386-91 [9779717.001]
  • [Cites] J Urol. 1999 Feb;161(2):472-5; discussion 475-6 [9915429.001]
  • [Cites] J Urol. 2005 Mar;173(3):824-9 [15711278.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65 [16174857.001]
  • [Cites] Eur Urol. 2005 Dec;48(6):885-94 [16126333.001]
  • [Cites] Lancet. 2006 Mar 4;367(9512):754-65 [16517276.001]
  • [Cites] J Clin Oncol. 2006 Dec 10;24(35):5503-11 [17158535.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4370-8 [17906202.001]
  • [Cites] Eur J Cancer. 2007 Nov;43(17):2553-8 [17949969.001]
  • [Cites] Jpn J Clin Oncol. 2008 Apr;38(4):281-7 [18321891.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):113-22 [12506179.001]
  • (PMID = 19906660.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2813544
  •  go-up   go-down


44. Casey RG, Aktar M, Hegarty P, Butler M, Thornhill JA: A prospective 10 year audit of a single Irish centre's experience of retroperitoneal lymph node dissection for metastatic testis cancer. Surgeon; 2008 Oct;6(5):294-6
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective 10 year audit of a single Irish centre's experience of retroperitoneal lymph node dissection for metastatic testis cancer.
  • BACKGROUND: Retro-peritoneal lymph node dissection (RPLND) following chemotherapy is critical in advanced germ cell tumours with residual retro-peritoneal masses.
  • Post-chemotherapy RPLND is more extensive, may require adjacent organ resection and has higher morbidity.
  • The study aim was to analyse patient demographics, clinical stage, surgical procedures and cure rates following RPLND.
  • METHODS: An RPLND database (1994-2005) was analysed prospectively for demographics, pre/post-RPLND staging, chemotherapy regimen, cure, follow-up and early/late morbidity and mortality.
  • Clinical stage at presentation was; IV (16), III (19), II (27), I (11) and prior to RPLND was IV (12), III (6), II (55), I (0).
  • Eleven patients with stage I disease progressed prior to RPLND.
  • Seventy-one patients received cisplatin-based chemotherapy with partial response (49), minimal response (14), no response (7), disease progression (3) and 13 patients required salvage chemotherapy.
  • CONCLUSIONS: The decision to perform post-chemotherapy RPLND depends on the possibility of viable tumour or teratoma and surgical morbidity.
  • [MeSH-major] Lymph Node Excision. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Humans. Ireland. Length of Stay / statistics & numerical data. Lymphatic Metastasis / pathology. Male. Medical Audit. Middle Aged. Neoplasm Staging. Prospective Studies. Retroperitoneal Space / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18939377.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


45. Lopes LF, Sonaglio V, Ribeiro KC, Schneider DT, de Camargo B: Improvement in the outcome of children with germ cell tumors. Pediatr Blood Cancer; 2008 Feb;50(2):250-3
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement in the outcome of children with germ cell tumors.
  • PURPOSE: To describe the clinical characteristics and estimate the survival of children and adolescents with germ cell tumors treated with cisplatin-based combination chemotherapy according to three different protocols in Brazil.
  • METHODS: From 1983 to 1997, 106 patients were treated at the Hospital do Cancer, Sao Paulo for a diagnosis of germ cell tumor.
  • RESULTS: Patients were treated with only surgery (n = 32), surgery and radiotherapy (n = 1) and chemotherapy (n = 73).
  • From 1983 to 1986 (period I), there were 30 patients and 21 received chemotherapy according to the modified VAB-6 protocol.
  • Twenty-two of 35 patients registered between 1987 and 1991 (period II) were treated with EPO/VAC combination chemotherapy.
  • From 1991 to 1997 (period III), there were 41 patients and 31 received chemotherapy according to the Brazilian TCG-91 protocol.
  • Important prognostic factors included stage (P < 0.001), metastatic status (P < 0.001) and surgical procedure at diagnosis (P < 0.001).
  • An incremental improvement in outcomes was noted across the periods of treatment (P = 0.070).
  • Five-year OS was respectively 42.9 +/- 10.8%, 53.9 +/- 11.4% and 80.6 +/- 7.1% for periods I, II, and III for the patients who received chemotherapy.
  • CONCLUSION: An improvement in the survival of children with germ cell tumors was achieved in the most recent trial (TCG-91) with a risk adapted approach incorporating only cisplatin and etoposide.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / therapy. Ovarian Neoplasms / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17554793.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Géczi L, Gomez F, Bak M, Bodrogi I: The incidence, prognosis, clinical and histological characteristics, treatment, and outcome of patients with bilateral germ cell testicular cancer in Hungary. J Cancer Res Clin Oncol; 2003 May;129(5):309-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence, prognosis, clinical and histological characteristics, treatment, and outcome of patients with bilateral germ cell testicular cancer in Hungary.
  • PURPOSE: To examine the incidence, prognosis, clinical and histological characteristics, treatment, and outcome of patients with bilateral testicular cancer in the referral center in Hungary, to determine which parameters might predict a second testicular tumor. METHODS: .
  • Clinical parameters-such as time of original surgery, histology of primary tumor, extent of the disease, serum marker concentrations, history of testicular abnormalities, treatment, response to treatment, follow-up period, data on second carcinoma-of bilateral testicular tumors among the 2,386 patients with testicular cancer treated between November 1988 and November 1998 were analyzed.
  • RESULTS: The incidence of patients with synchronous testicular tumor was 0.8% (19 of 2,386 patients).
  • The clinical stages were 8 I/A, 5 I/B, 1 II/A, 2 II/B, 1 III/A, and 2 III/B.
  • Median follow-up time was 93 months and the 5-year overall survival was 84%.
  • The incidence of patients with metachronous testicular cancer (median age 28 years and 35 years at first and second tumor diagnosis) was 2.2% (53 of 2,386 patients) and the median time to second tumor was 76 months (range 18-203 months).
  • The clinical stages at the first and second tumor diagnosis were: 14 I/A, 21 I/B, 15 II/A, 2 II/B, and 1 III/B, and 26 I/A, 16 I/B, 3 II/A, 1 II/B, 7 III/B, respectively.
  • The median follow-up time was 42 months and the 5-year overall survival was 93%.
  • In thirteen patients with metachronous cancers, two family histories of testicular cancer, five cases of undescended testicles, seven cases of testicular atrophy, and one case of azoospermia were detected.
  • There was a non-significant trend to a longer cancer interval after chemotherapy and radiotherapy and a tendency to a greater incidence of asynchronous seminoma after chemotherapy.
  • Clinical stage I tumors were more frequent in the surveyed group than among patients not followed up according to the institutional protocol ( P = 0.01), but the survival rate was good in both groups.
  • Seminoma as a second tumor was diagnosed in an older age group (median 38 years, range 25-49 years) than nonseminoma (median 32 years, range 21-51 years, P < 0.045).
  • The interval till the appearance of a metachronous testicular cancer depended on tumor histology: in seminoma cases it was longer than in nonseminoma cases (median time: 121 months versus 50 months, P = 0.002).
  • CONCLUSIONS: The overall incidence of bilateral testicular cancer in the referral center in Hungary was 3%.
  • We could not identify clinical factors which predicted a higher risk for metachronous testicular cancer.
  • With regular follow-up the early diagnosis of second testicular tumors is probable; therefore education, self-examination of the remaining testicle, and long-term follow-up are important in early detection.
  • [MeSH-major] Germinoma. Neoplasms, Second Primary. Testicular Neoplasms
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Chorionic Gonadotropin, beta Subunit, Human / blood. Humans. Hungary / epidemiology. Incidence. Male. Middle Aged. Neoplasm Staging. Orchiectomy. Prognosis. Radiotherapy, Adjuvant. Risk Factors. Self-Examination. Seminoma / blood. Seminoma / epidemiology. Seminoma / pathology. Seminoma / therapy. Survival Analysis. Treatment Outcome. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 1993;23(1):115-8; discussion 119 [8477771.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):547-52 [9690548.001]
  • [Cites] Drugs. 1999 Aug;58(2):257-81 [10473019.001]
  • [Cites] J Natl Cancer Inst. 1991 Oct 2;83(19):1391-5 [1656057.001]
  • [Cites] Eur J Cancer. 1998 Aug;34(9):1363-7 [9849418.001]
  • [Cites] Oncology. 2001;60(3):228-34 [11340374.001]
  • [Cites] Eur J Cancer. 1993;29A(6):874-6 [8387319.001]
  • [Cites] Br J Urol. 1988 Oct;62(4):374-6 [2847848.001]
  • [Cites] BJU Int. 2000 May;85(7):864-8 [10792167.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2061-5 [8683237.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3126-32 [8955658.001]
  • [Cites] Br J Urol. 1980 Apr;52(2):158-62 [6107141.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 2):2630-2 [10068265.001]
  • [Cites] Urology. 1999 Oct;54(4):714-8 [10510934.001]
  • [Cites] J Natl Cancer Inst. 1996 Jun 5;88(11):727-33 [8637026.001]
  • [Cites] Eur J Cancer. 1997 Feb;33(2):244-52 [9135496.001]
  • [Cites] Eur Urol. 1993;23(1):120-2 [8386640.001]
  • [Cites] Ann Surg Oncol. 1997 Jun;4(4):342-8 [9181235.001]
  • [Cites] Cancer. 1991 Sep 1;68(5):1082-5 [1655215.001]
  • (PMID = 12748851.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  •  go-up   go-down


47. Sundström J, Salminen E, Nurmi M, Toppari J, Pöllänen P, Pelliniemi LJ, Huhtala S, Rajala P, Laato M: Management of testicular cancer--16 years' experience from southwest Finland. Scand J Urol Nephrol; 2001 Feb;35(1):21-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of testicular cancer--16 years' experience from southwest Finland.
  • OBJECTIVE: This study investigated the outcome of testicular cancer treatment in Finland.
  • MATERIAL AND METHODS: Data on 88 testicular cancer patients treated in Turku University Central Hospital between 1976 and 1992 were studied to analyse outcome and survival.
  • Two seminoma patients relapsed (5%) and one patient died of progressive disease (3%; initially stage II seminoma).
  • Eleven non-seminoma patients relapsed (22%), nine of whom were cured with chemotherapy.
  • Four non-seminoma patients died of progressive disease (8%; initially one stage I non-seminoma and three stage III non-seminomas).
  • The median time to relapse after the completion of treatment was 9 months (range 3-50 months).
  • Most relapses (73% of the non-seminoma relapses) were found among the stage I non-seminoma patients who had not received adjuvant chemotherapy, while none of the stage I seminoma patients relapsed (p = 0.007).
  • CONCLUSIONS: Close surveillance is important for all non-seminoma patients to guarantee the early detection and treatment of recurrent disease.
  • Treatment and surveillance should be covered by national guidelines and be conducted in centres with special interest in this rare but mostly curable cancer.
  • [MeSH-major] Carcinoma / pathology. Carcinoma / therapy. Seminoma / pathology. Seminoma / therapy. Testicular Neoplasms / pathology. Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Finland / epidemiology. Follow-Up Studies. Humans. Male. Middle Aged. Orchiectomy / methods. Probability. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11291682.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


48. Lagrange JL, Ramaioli A, Theodore CH, Terrier-Lacombe MJ, Beckendorf V, Biron P, Chevreau CH, Chinet-Charrot P, Dumont J, Delobel-Deroide A, D'Anjou J, Chassagne C, Parache RM, Karsenty JM, Mercier J, Droz JP, Radiation Therapy Group and the Genito-Urinary Group of the French Federation of Cancer Centres: Non-Hodgkin's lymphoma of the testis: a retrospective study of 84 patients treated in the French anticancer centres. Ann Oncol; 2001 Sep;12(9):1313-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma of the testis: a retrospective study of 84 patients treated in the French anticancer centres.
  • Primary non-Hodgkin's lymphoma of the testicle is rare.
  • Disease was classified as stages I in 42 cases, stages II in 19 and stages III-IV in 23.
  • Diffuse large B-cell lymphoma was diagnosed in 75% of cases.
  • Treatment included orchidectomy and radiotherapy and/or chemotherapy.
  • A complete response was obtained in 72.6% of the patient population and in 100%, 68% and 33% of stage I, II and III-IV disease respectively.
  • Recurrence occurred in 32 cases and the most frequent site was the central nervous system: six of these patients presented stage I disease.
  • Median overall survival was 32 months for the entire population, 52 months for stage I, 32 months for stage II, and 12 months for stage III-IV cases (P < 0.0001).
  • Among patients presenting stage I disease, no difference was found between those treated with combined surgery and chemotherapy or surgery followed or not followed by radiotherapy.
  • This study confirms that non-Hodgkin's lymphoma of the testicle carries a poor prognosis.
  • Systemic adjuvant chemotherapy should be discussed because of the high recurrence rate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11697846.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


49. Debrah AY, Mand S, Specht S, Marfo-Debrekyei Y, Batsa L, Pfarr K, Larbi J, Lawson B, Taylor M, Adjei O, Hoerauf A: Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis. PLoS Pathog; 2006 Sep;2(9):e92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Presently used antifilarial drugs are able to strongly reduce transmission and will thus ultimately lower the burden of morbidity associated with the infection, however, a chemotherapeutic principle that directly induces a halt or improvement in the progression of the morbidity in already infected individuals would constitute a major lead.
  • In search of such a more-effective drug to complement the existing ones, in an area endemic for bancroftian filariasis in Ghana, 33 microfilaremic and 18 lymphedema patients took part in a double-blind, placebo-controlled trial of a 6-wk regimen of 200 mg/day doxycycline.
  • Four months after doxycycline treatment, all patients received 150-200 microg/kg ivermectin and 400 mg albendazole.
  • Lymphedema patients were additionally monitored for stage (grade) of lymphedema and the circumferences of affected legs.
  • The extent of disease in lymphedema patients significantly improved following doxycycline, with the mean stage of lymphedema in the doxycycline-treated patients being significantly lower compared to placebo patients 12 mo after treatment.
  • In conclusion, a 6-wk regimen of antifilarial treatment with doxycycline against W. bancrofti showed a strong macrofilaricidal activity and reduction in plasma levels of VEGF-C/sVEGFR-3, the latter being associated with amelioration of supratesticular dilated lymphatic vessels and with an improvement of pathology in lymphatic filariasis patients.
  • [MeSH-major] Doxycycline / therapeutic use. Elephantiasis, Filarial / drug therapy. Elephantiasis, Filarial / pathology. Filaricides / therapeutic use. Vascular Endothelial Growth Factor C / blood. Vascular Endothelial Growth Factor Receptor-3 / blood
  • [MeSH-minor] Adult. Animals. Female. Humans. Intercellular Signaling Peptides and Proteins / blood. Lymphatic System / diagnostic imaging. Lymphatic System / drug effects. Male. Microfilariae / isolation & purification. Microfilariae / physiology. Middle Aged. Molecular Sequence Data. Parasitemia / parasitology. Testicular Hydrocele / parasitology. Testis / diagnostic imaging. Treatment Outcome. Ultrasonography. Wolbachia / isolation & purification

  • Genetic Alliance. consumer health - Lymphatic filariasis.
  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Microbiol Immunol. 1999;43(3):279-83 [10338198.001]
  • [Cites] Trends Immunol. 2004 Jul;25(7):387-95 [15207507.001]
  • [Cites] Clin Infect Dis. 2006 Apr 15;42(8):1081-9 [16575724.001]
  • [Cites] Parasitol Today. 2000 Apr;16(4):135 [10725894.001]
  • [Cites] J Submicrosc Cytol Pathol. 2001 Jan-Apr;33(1-2):125-31 [11686393.001]
  • [Cites] Science. 2002 Mar 8;295(5561):1892-5 [11884755.001]
  • [Cites] Southeast Asian J Trop Med Public Health. 1980 Mar;11(1):32-9 [7403952.001]
  • [Cites] Trop Med Int Health. 2005 Sep;10(9):818-25 [16135187.001]
  • [Cites] Development. 1996 Dec;122(12):3829-37 [9012504.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1599-604 [9563467.001]
  • [Cites] EMBO J. 2001 Feb 15;20(4):672-82 [11179212.001]
  • [Cites] Ann N Y Acad Sci. 2002 Dec;979:94-110 [12543720.001]
  • [Cites] Am J Hum Genet. 2000 Aug;67(2):295-301 [10856194.001]
  • [Cites] Filaria J. 2003 Feb 7;2(1):2 [12605722.001]
  • [Cites] Trop Med Int Health. 1998 Jan;3(1):41-5 [9484967.001]
  • [Cites] Oncol Rep. 2005 May;13(5):931-6 [15809760.001]
  • [Cites] Lancet. 1994 Mar 5;343(8897):597 [7906341.001]
  • [Cites] Am J Trop Med Hyg. 2004 Jul;71(1):2-16 [15238682.001]
  • [Cites] Lancet. 2001 May 5;357(9266):1415-6 [11356444.001]
  • [Cites] Trans R Soc Trop Med Hyg. 2004 Nov;98(11):627-34 [15363642.001]
  • [Cites] Expert Rev Anti Infect Ther. 2003 Dec;1(4):571-7 [15482154.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):1988-92 [8700872.001]
  • [Cites] Trends Parasitol. 2003 Mar;19(3):105-9 [12643989.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):426-30 [12888807.001]
  • [Cites] Microbes Infect. 2000 Aug;2(10):1147-57 [11008105.001]
  • [Cites] Am J Trop Med Hyg. 2004 Nov;71(5 Suppl):iii, 1-46 [15574967.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):124-7 [12077591.001]
  • [Cites] Parasitol Today. 1999 Nov;15(11):437-42 [10511685.001]
  • [Cites] Microbes Infect. 2003 Apr;5(4):261-73 [12706439.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1996 Jul-Aug;90(4):423-8 [8882196.001]
  • [Cites] Lancet. 2000 Apr 8;355(9211):1242-3 [10770311.001]
  • [Cites] Trends Parasitol. 2003 Nov;19(11):516-22 [14580963.001]
  • [Cites] Ann Trop Med Parasitol. 1996 Feb;90(1):39-48 [8729626.001]
  • [Cites] J Biol Chem. 2001 Jun 1;276(22):19166-71 [11279005.001]
  • [Cites] Ann Trop Med Parasitol. 1993 Jun;87(3):247-58 [8257235.001]
  • [Cites] Filaria J. 2003 Mar 12;2(1):5 [12691606.001]
  • [Cites] Ann Trop Med Parasitol. 2004 Oct;98(7):685-96 [15521106.001]
  • [Cites] Trop Med Int Health. 2004 Oct;9(10 ):1111-4 [15482404.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1995 Jan-Feb;89(1):72-4 [7747314.001]
  • [Cites] Lancet. 2005 Jun 18-24;365(9477):2116-21 [15964448.001]
  • [Cites] Curr Opin Cell Biol. 1998 Apr;10(2):159-64 [9561839.001]
  • [Cites] EMBO J. 1996 Apr 1;15(7):1751 [8612600.001]
  • [Cites] Int J Hematol. 2004 Jul;80(1):29-34 [15293565.001]
  • [Cites] J Endotoxin Res. 2003;9(6):390-4 [14733727.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1997 Jan-Feb;91(1):78-81 [9093637.001]
  • [Cites] Trop Med Int Health. 2005 Jul;10(7):698-705 [15960709.001]
  • [Cites] Nat Med. 2001 Feb;7(2):192-8 [11175850.001]
  • [Cites] Trop Med Parasitol. 1993 Mar;44(1):40-4 [8516632.001]
  • [Cites] Science. 1997 May 30;276(5317):1423-5 [9162011.001]
  • [Cites] Adv Parasitol. 2005;60:245-84 [16230105.001]
  • [Cites] J Biol Chem. 1998 Apr 3;273(14):8413-8 [9525952.001]
  • [Cites] Ann Trop Med Parasitol. 1998 Jul;92(5):587-94 [9797832.001]
  • [Cites] Trans R Soc Trop Med Hyg. 2000 Mar-Apr;94(2):205-11 [10897370.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1996 Jan-Feb;90(1):55-6 [8730313.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):724-30 [15637689.001]
  • [Cites] Infect Dis Clin North Am. 1993 Sep;7(3):619-33 [8254163.001]
  • [Cites] Parasite Immunol. 2001 Jul;23(7):401-9 [11472559.001]
  • [Cites] Filaria J. 2003 Feb 27;2(1):3 [12636874.001]
  • [Cites] Microsc Res Tech. 2001 Oct 15;55(2):122-45 [11596157.001]
  • [Cites] Trans R Soc Trop Med Hyg. 2004 Aug;98(8):462-72 [15186934.001]
  • [Cites] N Engl J Med. 2002 Dec 5;347(23):1841-8 [12466508.001]
  • [Cites] Ann Trop Med Parasitol. 2000 Jun;94(4):353-64 [10945045.001]
  • [Cites] Nat Med. 2001 Feb;7(2):199-205 [11175851.001]
  • [Cites] Andrologia. 1980 Nov-Dec;12(6):564-76 [6162406.001]
  • [Cites] Ann Trop Med Parasitol. 1999 Jun;93(4):367-77 [10656038.001]
  • [Cites] Med Microbiol Immunol. 2003 Nov;192(4):211-6 [12684759.001]
  • [Cites] Parasite Immunol. 2005 Jan-Feb;27(1-2):9-16 [15813718.001]
  • [Cites] Am J Trop Med Hyg. 1995 Mar;52(3):258-61 [7694968.001]
  • [Cites] J Exp Med. 2000 Apr 17;191(8):1429-36 [10770808.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3566-70 [7724599.001]
  • [Cites] Parasitol Today. 2000 Dec;16(12):544-8 [11121854.001]
  • [Cites] Filaria J. 2006 Feb 05;5:1 [16457735.001]
  • [Cites] Trans R Soc Trop Med Hyg. 2001 Sep-Oct;95(5):534-6 [11706668.001]
  • [Cites] Am J Trop Med Hyg. 1991 Jun;44(6):691-5 [1858970.001]
  • [Cites] J Infect Dis. 1995 Mar;171(3):755-8 [7876636.001]
  • [Cites] EMBO J. 2001 Mar 15;20(6):1223-31 [11250889.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14389-94 [9826710.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):548-53 [9435229.001]
  • [Cites] Ann N Y Acad Sci. 2003 Jun;990:444-9 [12860672.001]
  • [Cites] Am J Trop Med Hyg. 1992 Jun;46(6):745-51 [1621900.001]
  • (PMID = 17044733.001).
  • [ISSN] 1553-7374
  • [Journal-full-title] PLoS pathogens
  • [ISO-abbreviation] PLoS Pathog.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AF081198/ CAA63907; RefSeq/ NM/ 002020
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Filaricides; 0 / Intercellular Signaling Peptides and Proteins; 0 / Vascular Endothelial Growth Factor C; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3; N12000U13O / Doxycycline
  • [Other-IDs] NLM/ PMC1564427
  •  go-up   go-down


50. Visco C, Medeiros LJ, Mesina OM, Rodriguez MA, Hagemeister FB, McLaughlin P, Romaguera JE, Cabanillas F, Sarris AH: Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy? Clin Lymphoma; 2001 Jun;2(1):40-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy?
  • This study was designed to determine response, outcome, and patterns of failure of patients with non-Hodgkin's lymphoma who presented with a testicular mass.
  • Anderson Cancer Center between 1969 and 1999 treated with doxorubicin-based regimens and with radiotherapy and/or intrathecal therapy were considered for this study.
  • Ann Arbor stage (AAS) was I in 22 patients, II in 7 patients, III in 1 patient, and IV in 13 patients.
  • All 43 patients had intermediate-grade lymphomas according to the Working Formulation, and all 31 tumors assessed immunophenotypically were large B-cell lymphoma according to the World Health Organization classification.
  • Thirty-four patients achieved complete remission, 19 of whom relapsed, and 5 failed initial therapy.
  • Progression-free survival for patients with AAS I/II vs. III/IV was 36% +/- 13% vs. 0%, respectively (P = 0.004).
  • At 10 years, the actuarial probability of failure in the central nervous system was 34% +/- 9% and was 21% +/- 9% in contralateral testis.
  • Doxorubicin-based regimens alone appear unable to cure most patients with lymphoma involving the testis, but CHOP with prophylactic intrathecal therapy and adjuvant scrotal radiotherapy appears promising.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Testicular Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11707869.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-16672
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


51. Spiess PE, Brown GA, Pisters LL, Liu P, Tu SM, Evans JG, Kamat AM, Black P, Tannir NM: Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? Cancer; 2006 Oct 1;107(7):1503-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?
  • BACKGROUND: The presence of viable tumor in the surgical specimen after postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) is associated with an increased risk of disease progression.
  • The objective of this study was to determine whether the presence of viable tumor in the surgical specimen could be predicted.
  • METHODS: Between 1980 and 2003, 236 patients underwent PC-RPLND for clinical Stage IIA or III nonseminomatous germ cell tumors (NSGCT).
  • The authors retrospectively reviewed the medical records of those patients for pertinent clinical and treatment-related outcomes.
  • A multivariate logistic regression analysis was used to evaluate whether clinical parameters were capable of predicting the presence of viable tumor in the surgical specimen.
  • RESULTS: International Germ Cell Consensus Classification (IGCCC) risk categories could be assigned to 218 patients, with 101 patients in the good-risk category, 32 patients in the intermediate-risk category, and 85 patients in the poor-risk category.
  • The incidence of viable tumor in the good-risk, intermediate-risk, and poor-risk categories was similar (17.8%, 15.6%, and 15.3%, respectively); however, the risk categories predicted disease-specific and recurrence-free survival (P = .022 and P < .0001, respectively).
  • On multivariate analysis, an elevated serum alpha-fetoprotein (AFP) level prior to PC-RPLND (P = .05) and the size of the retroperitoneal mass on pathology review (P = .02) were predictive of viable tumor in the surgical specimen.
  • CONCLUSIONS: Although IGCCC risk categories were correlated with disease-related outcomes, the risk groups had similar incidences of viable tumor.
  • Elevated serum AFP levels prior to surgery and the size of the retroperitoneal mass in the resected specimen may help to predict viable tumor in the PC-RPLND specimen.
  • [MeSH-major] Lymph Nodes / pathology. Neoplasms, Germ Cell and Embryonal / pathology. Testicular Neoplasms / drug therapy. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Disease-Free Survival. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Pathology, Surgical. Prognosis. Retroperitoneal Space. Risk. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Malignant germ cell tumor.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16944534.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


52. Spiess PE, Brown GA, Liu P, Tu SM, Tannir NM, Evans JG, Kamat AM, Kassouf W, Pisters LL: Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection. J Urol; 2007 Jan;177(1):131-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection.
  • PURPOSE: We evaluated the recurrence pattern in patients with nonseminomatous germ cell tumors treated with post-chemotherapy retroperitoneal lymph node dissection and determined the optimal surveillance strategy in these patients.
  • MATERIALS AND METHODS: Between 1980 and 2003, 236 patients with clinical stage IIA-III nonseminomatous germ cell tumors underwent post-chemotherapy retroperitoneal lymph node dissection.
  • Patients with increased preoperative tumor markers (alpha-fetoprotein greater than 15 ng/ml and/or beta-human chorionic gonadotropin greater than 2.2 U/ml) were excluded from study resulting in 198 patients for analysis.
  • We retrospectively reviewed medical records for pertinent clinical and treatment related outcomes.
  • In our patient population recurrence developed in 45 (23%) patients and 22 (11%) died of disease at a median followup of 41 months (range 6 to 250) after retroperitoneal lymph node dissection.
  • RESULTS: The clinical stage of testis cancer was IIA in 17, IIB in 49, IIC in 83 and III in 49 patients.
  • Of the cases of recurrence 21 (46.7%) were in those of clinical stage III, 18 (40%) stage IIC and 6 (11.8%) stage IIB disease.
  • CONCLUSIONS: Based on the recurrence pattern we propose stage specific surveillance guidelines for the followup of patients after post-chemotherapy retroperitoneal lymph node dissection.
  • [MeSH-major] Lymph Node Excision. Neoplasm Recurrence, Local / epidemiology. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / surgery. Testicular Neoplasms / drug therapy. Testicular Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17162023.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement